Podcasts about DOI

“How do we work with gravity to be healthier and stronger?” explains Brennan Spiegel, M.D. Brennan Spiegel, M.D., a physician and professor whose work is focused on how emotion, physical experience, and the mind-body connection shape health, joins us today to explore the emerging field of biogravitational medicine and what it reveals about our relationship with gravity, the body, and health. - What is biograviational medicine? (~3:30) - The connection between health & biogravitational forces (~4:45) - How Spiegel got interested in this topic (~6:40) - How gravity affects IBS (~8:15) - What is EDS? (~12:00) - Holistic approach to gut health (~14:10) - The role of the microbiome & biogravitational medicine (~18:20) - The overarching role of gravity in our health (~24:00) - How to optimize your health through gravity (~26:00) - The effect on mental health (~31:10) -  A protocol for mental resilience (~34:00) - His current research (~35:30) - Accessible ways to improve your health through gravity (~39:35) - The mind-body connection (~41:45) - The role of HRV (~43:35) - Spiegel's dream study (~45:40) - The future of the field (~48:50) Referenced in the episode:  - Follow Spiegel on Instagram (@brennan_spiegel)  - Learn more about Spiegel (www.BrennanSpiegelMD.com)  - Pick up his book, Pull: How Gravity Shapes Your Body, Steadies the Mind, and Guides Our Health. - Check out his podcast (https://thegravitydoctors.com/)  - What's my Gravitype Quiz: https://chatgpt.com/g/g-68a51addf2cc819191559f3fd61d9e7d-what-s-my-gravitype  - Research on gravity's effect on the gut (DOI: 10.14309/ajg.0000000000002066)  - Research on mental gravity (https://doi.org/10.3390/e25091275) We hope you enjoy this episode, and feel free to watch the full video on YouTube! Whether it's an article or podcast, we want to know what we can do to help here at mindbodygreen. Let us know at: podcast@mindbodygreen.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

This week we review a recent multicenter, randomized trial pitting 2 different immunosuppressive therapeutic approaches against each other. How did a novel approach of everolimus + low dose tacrolimus compare to more standard MMF + standard, higher dose tacrolimus in avoidance of major adverse transplant events or complications? How did this first ever prospective trial in the pediatric heart transplantation world start and how difficult was it to perform in the absence of corporate or NIH support? Why can these data help inform FDA labelling for this novel approach and why is this important? Dr. Kevin Daly of Boston Children's Hospital shares his deep insights into this work this week!DOI: 10.1001/jama.2025.14338

Interviewee: Bassel Shanab, BS is a fourth-year medical student at the Yale School of Medicine.  Interviewer:  Lisa Meeks, PhD, MA, Guest Editor, Academic Medicine Supplement on Disability Inclusion in UME. Description: This episode of Stories Behind the Science sits down with Bassel Shanab (Yale School of Medicine), co-first author of “The Intersection of Disability, Race, Ethnicity, and Financial Background on Food Insecurity Among Medical Students,” part of the Academic Medicine supplement on Disability Inclusion in UME. We move beyond prevalence rates to the lived realities behind them—and why hunger so often hides in plain sight in elite training environments. Bassel shares the personal experiences that shaped his questions, the multi-institutional data that sharpened the answers, and the practical moves any school can make now: screen routinely, get cost-of-living estimates right, normalize help-seeking, and invest in evidence-based campus supports. Along the way, we talk flourishing (not just “fixing”), student-led research networks, and why transparency beats stigma every time. Whether you're a dean, DRP, faculty member, or student, this conversation offers a humane roadmap from surviving to thriving. Links to the open-access article, and related tools are in the show notes. Transcript:  https://docs.google.com/document/d/184LJqvcAgHGmpHyOcaxOxRw4yetR7qrGPPin0HDX7i4/edit?usp=sharing   Bios:   Bassel Shanab, BS is a fourth-year medical student at the Yale School of Medicine. He holds a Bachelor of Arts in Biological Sciences and Global Health Studies from Northwestern University, graduating with distinction. His academic interests include medical education, cardiovascular health, social determinants of health, and health policy. Key Words:   Food insecurity Medical students Disability Race and ethnicity Underrepresented in medicine (URiM) Low-income background Intersectionality Student well-being Academic performance   Resources:  Article from Today's Talk The Intersection of Disability, Race, Ethnicity, and Financial Background on Food Insecurity Among Medical Students   Nguyen, Mytien MS; Shanab, Bassel M.; Khosla, Pavan; Boatright, Dowin MD, MBA, MHS; Chaudhry, Sarwat I. MD; Brandt, Eric J. MD, MHS; Hammad, Nour M. MS; Grob, Karri L. EdD, MA; Brinker, Morgan; Cannon, Caden; Cermack, Katherine; Fathali, Maha; Kincaid, John W.R. MS, MPhil; Ma, Yuxing Emily; Ohno, Yuu MS; Pradeep, Aishwarya; Quintero, Anitza MBA; Raja, Neelufar; Rooney, Brendan L.; Stogniy, Sasha; Smith, Kiara K.; Sun, George; Sunkara, Jahnavi; Tang, Belinda; Rubick, Gabriella VanAken MD; Wang, JiCi MD; Bhagwagar, Sanaea Z.; Luzum, Nathan; Liu, Frank MS; Francis, John S. MD, PhD; Meeks, Lisa M. PhD, MA; Leung, Cindy W. PhD. The Intersection of Disability, Race, Ethnicity, and Financial Background on Food Insecurity Among Medical Students. Academic Medicine 100(10S):p S113-S118, October 2025. | DOI: 10.1097/ACM.0000000000006156   https://journals.lww.com/academicmedicine/fulltext/2025/10001/the_intersection_of_disability,_race,_ethnicity,.12.aspx The Docs With Disabilities Podcast https://www.docswithdisabilities.org/docswithpodcast

This week on the Sausage of Science, Cara sits down with two trailblazing scholars shaping the future of paleoanthropology from the African continent outward. Dr. Palesa Madupe, postdoctoral researcher at the University of Copenhagen's Globe Institute, shares her pioneering work on enamel proteomics—reconstructing protein sequences from Paranthropus robustus and other South African hominins to unravel questions of taxonomy, sex determination, and sexual dimorphism. Joining her is Professor Becky Ackermann of the University of Cape Town, co-director of the Human Evolution Research Institute (HERI), whose influential research on evolutionary processes, phenotypic variation, and human diversity is reframing our understanding of our evolutionary story. Together, they highlight how African-led research is reshaping the global narrative of human origins, one fossil and one protein at a time. ------------------------------ Find the paper discussed in this episode: Madupe, P. P., Koenig, C., Patramanis, I., Rüther, P. L., Hlazo, N., Mackie, M., ... & Cappellini, E. (2025). Enamel proteins reveal biological sex and genetic variability in southern African Paranthropus. Science, 388(6750), 969-973. DOI: 10.1126/science.adt9539 ------------------------------ Contact Dr. Madupe: palesa.madupe@sund.ku.dk Contact Dr. Ackermann: becky.ackermann@uct.ac.za Human Evolution Research Institute (HERI) website: https://www.heriuct.co.za/ ------------------------------ Contact the Sausage of Science Podcast and Human Biology Association: Facebook: facebook.com/groups/humanbiologyassociation/, Website: humbio.org, Twitter: @HumBioAssoc Cara Ocobock, Host, Website: sites.nd.edu/cara-ocobock/, Email:cocobock@nd.edu, Twitter:@CaraOcobock Cristina Gildee, SoS Co-Producer, HBA Junior Fellow Website: cristinagildee.org, E-mail: cgildee@uw.edu,

Stephan von Düring, MD, and Eddy Fan, MD, PhD, join CHEST® Journal Podcast Moderator Matt Siuba, DO, MS, to discuss their research into the association between mechanical power within the first 24 hours and ICU mortality in adult patients with acute hypoxemic respiratory failure who are mechanically ventilated.  DOI: 10.1016/j.chest.2025.03.012 Disclaimer: The purpose of this activity is to expand the reach of CHEST content through awareness, critique, and discussion. All articles have undergone peer review for methodologic rigor and audience relevance. Any views asserted are those of the speakers and are not endorsed by CHEST. Listeners should be aware that speakers' opinions may vary and are advised to read the full corresponding journal article(s) for complete context. This content should not be used as a basis for medical advice or treatment, nor should it substitute the judgment used by clinicians in the practice of evidence-based medicine. 

Morgan Bailey, MD, joins CHEST® Journal Podcast Moderator Gretchen Winter, MD, to discuss her research into the frequency of pulmonary rehabilitation referrals among patients with pulmonary arterial hypertension and the factors associated with underutilization of pulmonary rehabilitation.  DOI: 10.1016/j.chest.2025.04.021 Disclaimer: The purpose of this activity is to expand the reach of CHEST content through awareness, critique, and discussion. All articles have undergone peer review for methodologic rigor and audience relevance. Any views asserted are those of the speakers and are not endorsed by CHEST. Listeners should be aware that speakers' opinions may vary and are advised to read the full corresponding journal article(s) for complete context. This content should not be used as a basis for medical advice or treatment, nor should it substitute the judgment used by clinicians in the practice of evidence-based medicine. 

What's the episode about?In this episode, get an overview of the 2025 Death, Dying and Disposal Conference held in Utrecht in the Netherlands What was the conference about? The below information was taken from the conference website.'Death is political and performs the political. This is evident not only in death itself, but also in the dead (who can become political actors), their bodies, the process of dying (which is, amongst others, infrastructurally related to political discourse and inequalities), and bereavement (which can also become apolitical act). The political aspects of this theme extend beyond national or international political institutions (such as governments, state actors, multinational corporations, or political or religious alliances) to encompass everybody and everything that has to do with (the exercise of) power andmoralities, e.g., families, kin, neighbourhoods, friendship networks. Our time together at DDD17 – as a short, but hopefully (partly)lasting DDD17 community – has come to a close. Over these past days, we've explored, listened, debated, and imagined — and we want to thank you for bringing such openness and curiosity to the theme of the Politics of Death. This may be the end of the conference, but we hope it is only the beginning of conversations on this theme. Let's continue them in whatever ways we can — in our research, our writing, our teaching, our work, our communities. We hope you are leaving as inspired as we are.Thanks to everybody who made this conference what is has been. A conference is made by its participants – together we were a fantastic community.'How do I cite the episode in my research and reading lists?To cite this episode, you can use the following citation:  Michael-Fox, B. and Visser, R. (2025) DDD17. The DeathStudies Podcast hosted by Michael-Fox, B. and Visser, R. Published 1October 2025. Available at: www.thedeathstudiespodcast.com,DOI: 10.6084/m9.figshare.30256387 What next?Check out more episodes or find out more about the hosts! Got a question? Get in touch.

BUFFALO, NY — October 1, 2025 — A new #research paper #featured as the #cover of Volume 17, Issue 9 of Aging-US was published on August 21, 2025, titled “Sex-specific longitudinal reversal of aging in old frail mice.” The study, led by first author Cameron Kato and corresponding author and Aging-US Editorial Board Member Irina M. Conboy from the University of California, Berkeley, reports that a combination of oxytocin and an Alk5 inhibitor (OT+A5i) significantly extended both lifespan and healthspan in frail, elderly, male mice. These rejuvenating effects were not seen in female mice, highlighting key biological differences between the sexes in their response to aging therapies. The researchers tested a dual-drug approach targeting two biological pathways that change with age. Oxytocin, a hormone that declines with aging and supports tissue repair, was combined with an Alk5 inhibitor that blocks the TGF-beta pathway. TGF-beta becomes overactive with age and contributes to chronic inflammation and tissue damage. In this study, frail mice at 25 months of age—roughly equivalent to 75 human years—were treated regularly with the OT+A5i combination. Male mice receiving the therapy lived over 70% longer than untreated controls and showed significant improvements in physical endurance, agility, and memory. According to hazard ratio analysis, the treated males were nearly three times less likely to die at any given time than untreated males. “Treatment of old frail male mice with OT+A5i resulted in a remarkable 73% life extension from that time, and a 14% increase in the overall median lifespan.” The therapy also reduced “biological noise” in circulating blood proteins—an established marker of aging—bringing those levels back to a more youthful state. Short-term benefits, were seen in both sexes, however, after four months of continuous treatment, only the male mice showed sustained improvement in systemic protein balance. Female mice did not experience significant gains in lifespan or healthspan, though middle-aged females did show improved fertility after treatment. These results underscore the importance of understanding sex-specific biology when developing treatments for aging. While the reasons for these differences remain unclear, the findings provide a new model for studying and designing longevity therapies. Oxytocin is already FDA-approved, and Alk5 inhibitors are currently in clinical trials, suggesting that this approach could be translated to humans. With strong results in aged and frail male animals, OT+A5i appears to be a promising candidate for improving late-life health and survival. DOI - https://doi.org/10.18632/aging.206304 Corresponding author - Irina M. Conboy - irina@generationlab.co Abstract video - https://www.youtube.com/watch?v=bpWxDd7hHhM Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206304 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, lifespan, healthspan, Alk5 inhibitor, oxytocin, sex-specific differences To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Warum lächelt sie obwohl sie gerade belästigt wird? Warum kooperieren Opfer bei Geiselnahmen oder Kidnapping? Warum bleiben manche Menschen viel zu lange in gewaltvollen Beziehungen? Das sind Fragen, die in der Forschung zu Coping, Traumareaktionen und Gewaltbeziehungen seit Jahren diskutiert werden und wir wollen das Ganze mal für euch einordnen. Diese Podcastfolge beleuchtet die psychologischen Überlebensstrategien, die in akuten und dauerhaften Gewaltsituationen greifen: von Appeasement-Strategien und dem viel diskutierten Fawning bis hin zum komplexen Phänomen des Trauma Bondings. **Quellen:** Bailey, B. et al. (2023): Appeasement: replacing Stockholm syndrome as a definition of a survival strategy, European Journal of Psychotraumatology, 14:1, 2161038, DOI: 10.1080/20008066.2022.2161038 Cantor and Price (2007) Carnes, P. J. (1997). The Betrayal Bond: Breaking free of exploitive relationships. Deerfield Beach, FL: Health Communications. Dutton, D. G., & Painter, S. (1981). Traumatic bonding: The development of emotional attachments in battered women and other relationships of intermittent abuse. Victimology, 6(1–4), 139–155. Dutton, D. G. & Painter, S. (1993). Emotional attachments in abusive relationships: a test of traumatic bonding theory. In: Violence and Victims. Band 8, Nr. 2, 1993, S. 105–120. Fonseca, N. de Q. L., & Oliveira, B. Q. de. (2021). Bindungstrauma: Konzepte, Ursachen und Mechanismen in intimen Beziehungen. Zenodo. Gilbert, P. (2000). The relationship of shame, social anxiety and depression: The role of the evaluation of social rank. Clinical Psychology & Psychotherapy, 7(3), 174–189. Gilligan, C. (1982). In a different voice: Psychological theory and women's development. Cambridge, MA: Harvard University Press. Newton, J. R. (2016). Appeasement: A behavioral strategy for survival in human and nonhuman primates. Behavioral and Brain Sciences, 39, e216. https://doi.org/10.1017/S0140525X15002364 Porges, S. W. (2001). The polyvagal theory: Phylogenetic substrates of a social nervous system. International Journal of Psychophysiology, 42(2), 123–146. Ridgeway, C. L. (2011). Framed by gender: How gender inequality persists in the modern world. Oxford, UK: Oxford University Press. Stockinger, L. (2023). Qualitative Untersuchung von Resilienz bei Dual-Trauma Couples (Masterarbeit, Universität Wien). Universität Wien. Walker, P. (2013). Complex PTSD: From surviving to thriving. Lafayette, CA: Azure Coyote. Walkup, M. (2008). Fawning: Trauma response and the “appease” reaction. In C. R. Figley (Ed.), Encyclopedia of Trauma (pp. 263–265). Thousand Oaks, CA: SAGE. Wood, J. T. (2013). Gendered lives: Communication, gender, and culture (10th ed.). Boston, MA: Cengage Learning. World Health Organization. (2012). Understanding and addressing violence against women. Geneva, Switzerland: World Health Organization.

Welcome to PICU Doc on Call, the podcast where we break down real-life cases from the pediatric intensive care unit and share practical insights for clinicians everywhere! I'm Dr. Monica Gray, and I'm joined by my co-host, Dr. Pradip Kamat.Today, we're diving into a fascinating case: a 13-year-old boy who suddenly developed muscle weakness and was found to have severe hypokalemia. After some detective work, he was diagnosed with familial hypokalemic periodic paralysis, a rare but important condition to recognize in the PICU.We'll discuss the genetic underpinnings, classic clinical features, and common triggers associated with this disorder. Additionally, we'll guide you through the differential diagnosis, key management strategies, such as potassium supplementation, and explain why genetic testing is so crucial. We'll also cover essential considerations for anesthesia and cardiac monitoring in these patients.Whether you're a pediatric intensivist or just interested in acute neuromuscular care, stick around for some practical pearls you can use on your next shift!Show Highlights:Clinical case discussion of a 13-year-old male patient with muscle weakness and hypokalemiaDiagnosis and management of familial hypokalemic periodic paralysisGenetic basis and mutations associated with hypokalemic periodic paralysis (CACNA1S and SCN4A)Physiological mechanisms underlying hypokalemic periodic paralysisCommon clinical presentations and triggers for episodes of muscle weaknessDifferential diagnoses for muscle weakness and hypokalemia in pediatric patientsLaboratory investigations to confirm hypokalemic periodic paralysisTreatment options for hypokalemic periodic paralysis, including potassium supplementation and prophylactic medicationsImportance of avoiding triggers and coordinating care with anesthesiaReferences:Fuhrman & Zimmerman - Textbook of Pediatric Critical Care Chapter 68: Weimer M et al. Acute neuromuscular disease and disorders page 840Rogers Textbook of Pediatric Intensive Care Medicine: Management of Sodium and Potassium Disorders. Pages 1876- 1883Reference 1: Weber F, Lehmann-Horn F. Hypokalemic Periodic Paralysis. 2002 Apr 30 [Updated 2018 Jul 26]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1338/Reference 2: Channelopathies. Clin Exp Pediatr. 2014;57(1):1-18. Published online January 31, 2014**DOI: https://doi.org/10.3345/kjp.2014.57.1.1**Reference 3: Statland JM, Fontaine B, Hanna MG, Johnson NE, Kissel JT, Sansone VA, Shieh PB, Tawil RN, Trivedi J, Cannon SC, Griggs RC. Review of the Diagnosis and Treatment of Periodic Paralysis. Muscle Nerve. 2018 Apr;57(4):522-530.

Dr Jess Stokes Parish (science communicator and ICU nurse) joins Preeya to tackle the beast of health misinformation. Why was Belle Gibson so effective at spreading false information? Was Belle unique or is the issue far more widespread? How do you spot dodgy health content online when there's so much of it and even qualified health professionals get confused at times? This episode includes practical tips to navigate this space (for both community members and health professionals). If you want to check out more about the CRABS framework referred to in the episode check out: https://www.jessicastokesparish.com/blog/crabs-the-credibility-frameworkAnti-Vaccine Cartoonhttps://museumandarchives.redcross.org.uk/objects/46927History of Vaccineshttps://historyofvaccines.org/vaccines-101/misconceptions-about-vaccines/history-anti-vaccination-movementsTaylor et al (2014). Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies. Vaccine.Hviid et al 2019. Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study. Annals of Internal Medicine.SKAI. 2025. What about autism?  https://skai.org.au/childhood/questions/what-about-autismPugh et al 2022. The unnaturalistic fallacy: COVID-19 vaccine mandates should not discriminate against natural immunity. BMJ Journal of Medical Ethics.CHOP. 2021. Immune System and Vaccines. https://www.chop.edu/vaccine-education-center/human-immune-system/immune-system-and-vaccineshttps://www.aihw.gov.au/reports/australias-health/what-are-determinants-of-healthHealth literacy, social media and misinformationhttps://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-022-13599-7Zang et al 2023. What Do We Mean When We Talk about Trust in Social Media? A Systematic Review. rXiv:2302.03671v1Lewandowsky et al (2012). Misinformation and its correction: continued influence and successful debiasing. DOI: 10.1177/1529100612451018Lewandowsky et al (2020). The Debunking Handbook 2020. DOI:10.17910/b7.1182Al Khaja, K.A.J., AlKhaja, A.K. & Sequeira, R.P. Drug information, misinformation, and disinformation on social media: a content analysis study. J Public Health Pol 39, 343–357 (2018). https://doi.org/10.1057/s41271-018-0131-2Denniss, E., Lindberg, R., Marchese, L.E. et al. #Fail: the quality and accuracy of nutrition-related information by influential Australian Instagram accounts. Int J Behav Nutr Phys Act 21, 16 (2024). https://doi.org/10.1186/s12966-024-01565-yMueller SM, Jungo P, Cajacob L, Schwegler S, Itin P, Brandt OThe Absence of Evidence is Evidence of Non-Sense: Cross-Sectional Study on the Quality of Psoriasis-Related Videos on YouTube and Their Reception by Health SeekersJ Med Internet Res 2019;21(1):e11935Chung et al (2012). Safe infant sleep recommendations on the internet: let's google it.  DOI:https://doi.org/10.1016/j.jpeds.2012.06.004Daraz et al (2019). Can patients trust online health information? a meta-narrative systematic review addressing the quality of health information on the internet. DOI: 10.1007/s116606-019-05109-0Stokes-Parish J. Navigating the Credibility of Web-Based Information During the COVID-19 Pandemic: Using Mnemonics to Empower the Public to Spot Red Flags in Health Information on the Internet. J Med Internet Res 2022;24(6):e38269doi: 10.2196/38269 Sunscreen MisinformationCathal O'Connor, Siobhán Rafferty, Michelle Murphy, A qualitative review of misinformation and conspiracy theories in skin cancer, Clinical and Experimental Dermatology, Volume 47, Issue 10, 1 October 2022, Pages 1848–1852, https://doi.org/10.1111/ced.15249Instagram: ⁠⁠⁠⁠@doctor.preeya.alexander⁠⁠⁠⁠Books: ⁠⁠⁠⁠Eat, Sleep, Play, Love⁠⁠⁠ by Dr Preeya Alexander⁠⁠⁠⁠Full Plate⁠⁠⁠⁠, out nowTo find out more about AIA Australia head to ⁠⁠www.aia.com.au⁠

Interviewees: Dr. Zoie Sheets, Resident Physician in the Departments of Medicine and Pediatrics at the University of Chicago; and Dr. Nalinda Charnsangavej, Associate Professor of Pediatrics and Residency Program Director at Dell Medical School at the University of Texas at Austin. Interviewer:  Lisa Meeks, PhD, MA, Guest Editor, Academic Medicine Supplement on Disability Inclusion in UME. Description: Preparing to Thrive: Supporting Learners with Disabilities Through the Undergraduate-to-Graduate Medical Education Transition This episode of Stories Behind the Science brings you an intimate conversation with Dr. Zoie Sheets (University of Chicago) and Dr. Nalinda Charnsangavej (Dell Medical School, UT Austin), co-authors of Preparing to Thrive, part of the Academic Medicine supplement on Disability Inclusion in Undergraduate Medical Education. We go beyond the article to uncover the motivations, lived experiences, and research that shaped their scholarship. Together, we explore four critical decision points that can shape the trajectory of disabled medical students as they move from UME to GME: Disclosure decisions Specialty selection Program selection Requesting and utilizing accommodations in residency Zoie and Nalinda share how research, mentorship, and community informed their work, and why bridging this “black box” transition period is essential for cultivating a more inclusive profession. Whether you're a program director, DRP, advisor, or student, this episode offers insights and concrete strategies to ensure learners are not just surviving this pivotal transition—but thriving. Resources and links to the open-access article, Disability Resource Hub, and related tools are in the show notes. Transcript: https://docs.google.com/document/d/1h4bh81klK-mfP3grm5LNzmYp-czCEP_haP704aJBekk/edit?usp=sharing Bios:   Nalinda Charnsangavej, MD is Associate Professor of Pediatrics at the Dell Medical School at the University of Texas at Austin where she serves as the pediatric residency program director. She serves as Co-Chair of the Disability in Graduate Medical Education group as part of the Docs with Disabilities Initiative and Co-Chair of the UME to GME Transitions Committee for the Disability Resource Hub -- the result of a collaboration between the ACGME and DWDI. As a program director, she is interested in fostering a healthy and supportive learning environment that promotes physician well-being and resilience. Her current work focuses on the transition from medical school to residency training and how to support learners with disabilities during this critical transition period. Outside of medical education, she enjoys spending time with her family, teaching her children how to cook, and attending Texas Longhorn sporting events. Zoie C. Sheets, MD, MPH is a resident physician in internal medicine and pediatrics (Med/Peds) at the University of Chicago. She is also a leader within the Docs with Disabilities Initiative, serving as Co-Chair of the Disability in Graduate Medical Education group and Co-Chair of the UME to GME Transitions Committee for the creation of a Disability Resource Hub — a collaboration between ACGME and DWDI. She believes deeply that increasing the number of disabled clinicians can transform medical education and practice, for providers and patients alike. Her current research focus centers on how graduate medical education can best support learners with disabilities, particularly during the challenging transition out of UME. In her free time, Zoie loves to read, re-watch too many medical dramas, and play with her two cats!  Key Words:   Disability inclusion Medical education Undergraduate medical education (UME) Graduate medical education (GME) UME–GME transition Disabled medical students Residency accommodations Program director support Disability Resource Professionals (DRPs) Academic Medicine  Resources:  Article from Today's Talk Sheets, Zoie C. MD, MPH; Fausone, Maureen MD, MA; Messman, Anne MD, MHPE; Ortega, Pilar MD, MGM; Ramsay, Jessica MD; Creasman, Megan MD, MA; Charnsangavej, Nalinda MD. Preparing to Thrive: Supporting Learners With Disabilities Through the Undergraduate-to-Graduate Medical Education Transition. Academic Medicine 100(10S):p S161-S165, October 2025. | DOI: 10.1097/ACM.0000000000006136   The Disability Resource Hub from ACGME and DocsWithDisabilities  https://bit.ly/DisabilityResourceHUB_GME   The Docs With Disabilities Podcast https://www.docswithdisabilities.org/docswithpodcast   Docs With Disabilities You Tube, Disability in Graduate Medical Education Videos https://www.youtube.com/playlist?list=PLc4XEizXENYw58ptzAgfxBA4q3uLRcmx6   Docs With Disabilities Disability in Graduate Medical Education Working Group https://www.docswithdisabilities.org/digme

Interviewees: Kirsten Brown, PhD Assistant Professor of Health Professions Education at the Uniformed Services University of the Health Sciences; as a short disclaimer, Kirsten's views do not represent the official policy or position of her employer.  Dionna Bidny, MD, MMUS  a first-year resident in Physical Medicine and Rehabilitation at the University of Pittsburgh Medical Center, currently completing her Transitional Year; and Abby Konoposky, PhD Senior Director of Medical Education Research in the Department of Psychiatry at Northwell Health. Interviewer:  Lisa Meeks, PhD, MA, Guest Editor, Academic Medicine Supplement on Disability Inclusion in UME. Description: This episode of Stories Behind the Science brings you an intimate conversation with Dr. Kirsten Brown (Uniformed Services University of the Health Sciences), Dr. Dionna Bidny (University of Pittsburgh Medical Center), and Dr. Abby Konopasky (Northwell Health), co-authors of Disability in Undergraduate Medical Education in the United States: A Scoping Review, part of the Academic Medicine supplement on Disability Inclusion in Undergraduate Medical Education. Drawing from over 80 publications, their study traces how disability in medical education has too often been framed through deficit and legal models, while leaving intersectionality and the voices of disabled learners largely absent. Together, we explore why this framing matters, what the literature reveals about gaps and progress, and how a critical perspective can re-shape the field. Our guests share the personal and professional motivations behind this ambitious review, the surprises and challenges they encountered, and their hopes for how this work can serve as both roadmap and catalyst. Whether you are a researcher, faculty member, disability resource professional, or student, this episode offers insights into the state of the field and inspiration for charting new directions. Resources and links to the open-access article, Disability Resource Hub, and related tools are in the show notes. Transcript: https://docs.google.com/document/d/1iUYE0Q-2TA1flXiMU6rum1S3dO-obE5DoA9J0mFmHlE/edit?usp=sharing Bios:   Kirsten Brown, PhD Dr. Kirsten Brown's research examines the intersection of disability, power, and social systems. Her work has appeared in the Journal of College Student Development, the Journal of Diversity in Higher Education, and Journal of Higher Education. She co-authored the book Disability in Higher Education: A Social Justice Approach. Dr. Brown prepared this chapter during non-work hours as an independent scholar and this publication did not receive funding from the federal government. The views expressed are solely those of the author and do not represent the official policy or position of the Uniformed Services University of the Health Sciences, the Henry M. Jackson Foundation for the Advancement of Military Medicine, the Department of Defense, or the U.S. Government.  Abigail Konopasky, PhD Abigail Konopasky holds doctorates in educational psychology from George Mason University and in linguistics from Princeton University. She is currently an Associate Professor and Director of Medical Education Research and Scholarship in the Psychiatry Department at Northwell Health. She conducts critical qualitative and mixed methods research in health professions education, with a focus on equity, Black feminism, and critical disability studies using functional linguistic and narrative methods and theories of agency. She serves on the editorial boards of Teaching and Learning in Medicine, Perspectives on Medical Education, and Advances in Health Sciences Education. Dionna Bidny, MD, MMus  Dionna is a first year resident at the University of Pittsburgh Medical Center in Physical Medicine and Rehabilitation (currently  in her  Transitional Year). She has a BS in biomedical engineering and an  MMus in Musicology; she incorporated her interest in accessibility in arts, sports, and healthcare spaces through research during both degrees. In medical school, she continued to study and lecture in the space of disability  justice and its intersections with art, identity,  and healthcare experience, all  while navigating  chronic illness and pursuit of her own  accommodation and access needs. In residency, she aims to continue her work in accessibility within arts and sports through community engagement and engineering innovation. Key Words:   Disability in medical education Undergraduate medical education (UME) Disability inclusion Scoping review Academic Medicine supplement Deficit model vs. asset model Legal framing of disability Intersectionality in medicine Disabled learners' voices Critical perspectives in medical education Equity in medical training Accommodations in medical education Disability justice Ableism in medicine Representation in health professions Research roadmap Diversity and inclusion in medicine Disability studies in medical education Inclusive curriculum Systemic barriers in medical education Resources:  Article from Today's Talk Maggio, Lauren A. PhD; Brown, Kirsten R. PhD; Costello, Joseph A. MSIS; Konopasky, Aaron PhD, JD; Bidny, Dionna MD, MMus; Konopasky, Abigail PhD. Disability in Undergraduate Medical Education in the United States: A Scoping Review. Academic Medicine 100(10S):p S64-S73, October 2025. | DOI: 10.1097/ACM.0000000000006154 https://journals.lww.com/academicmedicine/fulltext/2025/10001/disability_in_undergraduate_medical_education_in.5.aspx   The Docs With Disabilities Podcast https://www.docswithdisabilities.org/docswithpodcast

Just today in clinic, we had a patient, who was well into her third trimester, come to her regular scheduled appointment with new onset left-sided facial droop. Yeah, that's concerning! A complete history and physical was performed and the diagnosis was made of Bell's palsy. This is not a rare event and it can be extremely stressful for the affected mother to be because everybody knows facial droop is not normal! And we have recent data regarding this. In July 2025 in the Journal of Plastic, Reconstructive, and Aesthetic Surgery, authors confirmed that Bell's palsy can have real negative functional and psychosocial implications for those affected. So, in this episode, we are going to discuss Bell's palsy in pregnancy. How do we differentiate this from the more serious differential, which is a stroke? What about treatment? Listen in for details. 1. Wesley, Shaun R. MD; Vates, G. Edward MD, PhD; Thornburg, Loralei L. MD. Neurologic Emergencies in Pregnancy. Obstetrics & Gynecology 144(1):p 25-39, July 2024. | DOI: 10.1097/AOG.00000000000055752. Vrabec JT, Isaacson B, Van Hook JW. Bell's Palsy and Pregnancy.Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 2007;137(6):858-61. doi:10.1016/j.otohns.2007.09.009.3. Evangelista V, Gooding MS, Pereira L.Bell's Palsy in Pregnancy.Obstetrical & Gynecological Survey. 2019;74(11):674-678. doi:10.1097/OGX.00000000000007324. JPRAS (July 2025): https://www.jprasurg.com/article/S1748-6815(25)00328-6/fulltextSTRONG COFFEE PROMO: 20% Off Strong Coffee Company https://strongcoffeecompany.com/discount/CHAPANOSPINOBG

This week we review a recent report of the use of phenoxybenzamine for the reduction of SVR in children undergoing congenital heart surgery in India. How does this agent work and what might be the advantage versus other agents like nitroprusside or milrinone which are more commonly used? How does the cost of this agent (or phentolamine) compare with newer agents? We speak with Dr. Rohit Loomba of Lurie Children's Hospital. For those interested, in addition to working as a critical care cardiologist, Dr. Loomba is also a noted cardiac morphologist and his wonderful videos can be seen at the following web address:https://www.youtube.com/@Talking_HeartsToday's paper:DOI: 10.4103/jpbs.jpbs_868_25

In this episode of the Longevity & Aging Series, Girish Harinath from AgelessRx joins host Dr. Evgeniy Galimov to discuss a research paper he co-authored in Volume 17, Issue 4 of Aging-US, titled “Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results.” DOI - https://doi.org/10.18632/aging.206235 Corresponding author - Stefanie L. Morgan - stefanie@agelessrx.com Video interview - https://www.youtube.com/watch?v=7-NvskI8Ve0 Longevity & Aging Series - https://www.aging-us.com/longevity Abstract Design: This 48-week decentralized, double-blinded, randomized, placebo-controlled trial (NCT04488601) evaluated the long-term safety of intermittent low-dose rapamycin in a healthy, normative-aging human cohort. Participants received placebo, 5 mg or 10 mg compounded rapamycin weekly. The primary outcome measure was visceral adiposity (by DXA scan), secondary outcomes were blood biomarkers, and lean tissue and bone mineral content (by DXA scan). Established surveys were utilized to evaluate health and well-being. Safety was assessed through adverse events and blood biomarker monitoring. Results: Adverse and serious adverse events were similar across all groups. Visceral adiposity did not change significantly (ηp2 = 0.001, p = 0.942), and changes in blood biomarkers remained within normal ranges. Lean tissue mass (ηp2 = 0.202, p = 0.013) and self-reported pain (ηp2 = 0.168, p = 0.015) improved significantly for women using 10 mg rapamycin. Self-reported emotional well-being (ηp2 = 0.108, p = 0.023) and general health (ηp2 = 0.166, p = 0.004) also improved for those using 5 mg rapamycin. No other significant effects were observed. Conclusions: Low-dose, intermittent rapamycin administration over 48 weeks is relatively safe in healthy, normative-aging adults, and was associated with significant improvements in lean tissue mass and pain in women. Future work will evaluate benefits of a broader range of rapamycin doses on healthspan metrics for longevity, and will aim to more comprehensively establish efficacy. Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206235 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, rapamycin, geroscience, longevity, healthspan To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Send us a textThis week on Project Weight Loss, we're talking about the powerful practice of acceptance — not as resignation, but as a way to stop fighting yourself and create space for real change. I'll share how acceptance can help you break free from perfectionism, find peace with where you are, and take values-driven action toward your goals. Plus, we'll look at research from Forman & Butryn and others showing that acceptance-based approaches actually support weight loss and emotional well-being. Quotes of the week: “Acceptance doesn't mean resignation; it means understanding that something is what it is and that there is a way through it.” — Michael J. Fox, “If we can learn to welcome everything, including the difficult, knowing that this too is part of our becoming, then there is an invitation to heal, to grow, to live more fully.” — Oprah Winfrey. Citations:Forman, E.M., Butryn, M.L., et al. (2013). Acceptance-Based Behavioral Treatment for Weight Control: A Review and Future Directions. Behavior Therapy, 44(1), 77–88.Iturbe, F.M., Echeburúa, E., & Maiz, E. (2021). Effectiveness of Acceptance and Commitment Therapy for Weight Loss and Psychological Well-Being: A Systematic Review. Clinical Psychology & Psychotherapy, 28(6), 1364–1378.2024 Meta-Analysis: Acceptance and Commitment Therapy for Weight-Related Outcomes: A Meta-Analysis.(2024). [Details of journal and DOI can be added once published/located.]Let's go, let's get it done. Get more information at: http://projectweightloss.org

Are you on social media? Of course you are. So follow us! Twitter: @MemberTheGameInstagram: @MemberTheGameTwitch.tv/MemberTheGameYoutube.com/RememberTheGameFacebook.com/RememberTheGamePodcastTikTok.com/@MemberTheGameAnd if you want access to hundreds of bonus (ad-free) podcasts, along with multiple new shows EVERY WEEK, consider showing us some love over at Patreon. Subscriptions start at just $3/month, and 5% of our patreon income every month will be donated to our 24 hour Extra-Life charity stream at the end of the year!Patreon.com/RememberTheGameAnd you can check out Captain N's Retrotopia Podcast here:https://retrotopiapodcast.podbean.com/While I'm a picky eater when it comes to JRPGs, I'll never forget my first - Final Fantasy IV (FF2 on the SNES). I recently played the Pixel Remaster version for the first time, so I wanted to give Cecil and friends another round of RTG.I don't disagree with anyone that says Final Fantasy VI is the superior game, but IV isn't without its charm. I love the characters, betrayals, and combat system, and personally I like the linear party management of this one better to future entries where you can mix and match as you please. It's really wild to see how far JRPGs have come since Golbez's started robbing jewelry stores, and I think FF IV deserves its flowers for helping the series evolve from its basic NES counterparts.Captain N of the Retrotopia podcast joins me this week and we both geeked out pretty hard over this game. A couple dungeons (Dark Elf) and characters (Spoony Bard) got under our skin, but at the end of the day I think we agree that this is a must-play for fans of the genre, and a great place for someone new to Final Fantasy to get their feet wet. And before we argue with Tellah, I put together another edition of the Infamous Intro!This week, someone asks what the next big trend in gaming is going to be? What Mario moment blew my mind the most as a kid? And where doI stand on silent protagonists in games?Plus we play another round of 'Play One, Remake One, Erase One', too! This one features 3 Final Fantasy legends: Final Fantasy VI, Final Fantasy IX, and Final Fantasy X.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

BUFFALO, NY - September 24, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on September 22, 2025, titled “Loss of Trp53 results in a hypoactive T cell phenotype accompanied by reduced pro-inflammatory signaling in a syngeneic orthotopic mouse model of ovarian high-grade serous carcinoma.” In this study, led by first author Jacob Haagsma and corresponding author Trevor G. Shepherd from the Verspeeten Family Cancer Centre and Western University, Canada, researchers investigated how the loss of Trp53 – a critical tumor suppressor gene – affects immune responses in ovarian cancer. The team found that deleting Trp53 led to more aggressive tumor growth and a weaker immune response. These findings help explain why some ovarian tumors may be resistant to immunotherapy and point to new ways to improve treatment. High-grade serous ovarian carcinoma (HGSC) is a deadly cancer that is often diagnosed at a late stage. Immunotherapy, which enhances the body's immune system to fight cancer, has shown limited effectiveness in treating this type of cancer. To better understand why, the researchers developed a mouse model that closely mimics human HGSC. They injected ovarian epithelial cells, with and without Trp53, into the fallopian tubes, the origin site of most ovarian cancers. “In this study, we developed a syngeneic model reflecting both the site of origin and the genotype of early HGSC disease by deleting Trp53 in mouse oviductal epithelial (OVE) cells.” Mice injected with cells lacking Trp53 developed faster-growing and more invasive tumors, reflecting how the disease typically progresses in humans. These tumors also had fewer active T cells, which are immune cells responsible for attacking cancer. Moreover, the T cells that were present appeared less capable of responding to the tumor, creating an immune environment that allowed cancer to grow uncontrolled. Further analysis revealed that tumor cells without Trp53 had reduced activity in genes related to inflammation. These changes were associated with lower levels of key proteins that normally help immune cells detect and attack tumor cells. When the researchers collected tumor cells from the abdominal fluid of the mice—a condition that simulates advanced-stage disease—they observed even lower immune signaling than before. This suggests that as the tumor spreads, it becomes better at evading the immune system. This study highlights how early genetic mutations can shape the interaction between tumors and the immune system. In particular, the loss of Trp53 appears to trigger a chain of events that weakens immune surveillance and accelerates tumor progression. These findings emphasize the need to consider both genetic mutations and the tumor environment when designing immunotherapies for ovarian cancer. Understanding how genes like Trp53 influence immune behavior may lead to more effective treatments and help identify which patients are most likely to benefit from immunotherapy. DOI - https://doi.org/10.18632/oncotarget.28768 Correspondence to - Trevor G. Shepherd - tshephe6@uwo.ca Abstract video - https://www.youtube.com/watch?v=WFQw0psuC3M Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28768 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY — September 24, 2025 — A new #research paper was #published in Volume 17, Issue 8 of Aging-US on August 7, 2025, titled, “What is the clinical evidence to support off-label rapamycin therapy in healthy adults?” In this study, led by Jacob M. Hands from The George Washington University School of Medicine and Health Sciences, researchers analyzed current research to determine whether low-dose rapamycin can extend healthspan or delay aging in healthy adults. While studies in animals have shown promising results, this review found no clear clinical evidence that the same benefits apply to humans. The findings point to the urgent need for larger, better-designed human trials before recommending rapamycin for off-label use to prevent aging. Rapamycin, originally developed as a drug to suppress the immune system, has gained interest as a possible anti-aging therapy. It works by blocking a key cellular pathway called mTOR, which plays a role in growth and metabolism. In animal studies, blocking this pathway has extended lifespan. However, the translation of these results to humans remains uncertain. The current study examined clinical trials and observational studies involving healthy adults who took low doses of rapamycin or similar drugs. “This paper has reviewed trials of low-dose mTOR inhibition therapy in human subjects.” Some trials showed encouraging signs. For example, older adults treated with low-dose mTOR inhibitors showed stronger immune responses and fewer respiratory infections. Other studies suggested possible improvements in subjective well-being and physical performance, such as walking speed and strength. Still, none of the trials directly showed that rapamycin extends life or clearly slows the aging process. One small study using a biological aging model (PhenoAge) suggested that users might have reduced their biological age by nearly four years, but the estimate was based on average values, not individual patient data. There are also concerns about side effects. While short-term use seems safe, some studies reported increases in blood lipids and markers of inflammation. Research on muscle health produced contradictory findings—some studies suggest rapamycin might reduce the body's ability to build muscle. The impact on mental health is also unclear, with a few participants reporting increased anxiety during treatment. The researchers emphasize that rapamycin's role in human aging is still uncertain. Off-label use is growing among longevity clinics and individuals seeking anti-aging solutions, but there is no standard dose, and long-term safety is unknown. The authors advise that off-label use should be approached with caution, including careful monitoring and full disclosure about the limited evidence. Overall, while animal studies have demonstrated promising effects, human trials have not yet shown that rapamycin can safely or effectively slow aging or extend lifespan. More rigorous and well-controlled studies are necessary before the drug can be considered a reliable option for healthy adults interested in longevity interventions. DOI - https://doi.org/10.18632/aging.206300 Corresponding author - Jacob M. Hands - jacobhands@gwu.edu Abstract video - https://www.youtube.com/watch?v=cdWUenvB_mY Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY — September 23, 2025 — A new #research paper was #published in Volume 17, Issue 8 of Aging-US on August 7, 2025, titled “Senescent cell heterogeneity and responses to senolytic treatment are related to cell cycle status during senescence induction.” This study, led by first authors Francesco Neri and Shuyuan Zheng, together with corresponding authors Denis Wirtz, Pei-Hsun Wu, and Birgit Schilling from the Buck Institute for Research on Aging, the USC Leonard Davis School of Gerontology, and Johns Hopkins University, reveals that not all aging cells behave the same. The researchers identified key differences between senescent cell subtypes that may influence how well they respond to senolytic drugs. These findings could help guide the development of more effective therapies for age-related diseases. Senescent cells are aged or damaged cells that stop dividing and accumulate in tissues over time. While they play a role in wound healing and protecting against cancer early in life, they can drive chronic inflammation and tissue decline with age. Researchers are exploring ways to selectively remove these cells using senolytic drugs. However, the large variety of senescent cell types has made it difficult to design treatments that work for all of them. This study aimed to better understand the functional differences among senescent cell subpopulations. Using high-resolution imaging, the team analyzed thousands of human endothelial and fibroblast cells growing in the lab. They observed that cells that exited the cell cycle (stopped dividing) in a later phase showed stronger signs of senescence and were more sensitive to senolytic treatment. These cells also produced more IL-6, a molecule associated with inflammation. The findings suggest that DNA content, which varies depending on the cell cycle phase, plays an important role in how aging cells function and how they respond to drugs. “We found that G2-arrested senescent cells feature higher senescence marker expression than G1-arrested senescent cells.” This is the first clear evidence that senescent cells do not all respond equally to treatment. The results suggest that future senolytic therapies could be more successful if they are designed to target specific subtypes of senescent cells, especially those with greater inflammatory potential. While this research was conducted in laboratory cell cultures, it provides a foundation for studying how these findings apply to living tissues. Future work will examine whether similar patterns occur in the body and how this knowledge could lead to more precise and effective treatments for age-related conditions. Understanding the diversity of aging cells is key to developing therapies that are both safer and more targeted. DOI - https://doi.org/10.18632/aging.206299 Corresponding authors - Denis Wirtz — wirtz@jhu.edu, Pei-Hsun Wu — pwu@jhu.edu, and Birgit Schilling — bschilling@buckinstitute.org Abstract video - https://www.youtube.com/watch?v=x8bhKEFLzqA Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206299 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, cellular senescence, imaging, heterogeneity, senolytics, cell cycle To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

This week we replay an episode from 2 years ago on postoperative ectopic atrial tachycardia (EAT) following congenital heart surgery in children. Are there risk factors for this arrhythmia and are any modifiable? What is the 'go to' therapy used by the electrophysiologists at Children's LA for the acute and chronic treatment of this arrhythmia in the postoperative period? Is the presence of EAT in a postoperative congenital heart patient a marker for a worse outcome? These are amongst the questions posed to Children's of Los Angeles pediatric electrophysiologist, Dr. Jonathan Uniat. ·         DOI: 10.1007/s00246-022-03068-8

In this second-ever collaboration between SIDP's Breakpoints and ESCMID's Communicable podcasts, hosts Erin McCreary and Angela Huttner invite the two principal investigators and visionaries who spearheaded the Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE) trial, Nick Daneman and Rob Fowler from Sunnybrook Health Sciences Centre in Toronto, for a “deep dive into all things that went into this trial.” The BALANCE trial spanned over ten years investigating - as the acronym title suggests - whether a shorter treatment duration of seven days was non-inferior to the standard of care of fourteen days for bacteremia. The conversation covers everything from the initial hallway discussions that sparked the trial, the trial itself that screened over 36,000 patients and enrolled +3,600, its impact on clinical practice, key takeaways, and what's next for Daneman and Fowler. References: BALANCE Investigators, et al. Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections. N Engl J Med. 2025 March. DOI: https://doi.org/10.1056/NEJMoa2404991

In this second-ever collaboration between SIDP's Breakpoints and ESCMID's Communicable podcasts, hosts Erin McCreary and Angela Huttner invite the two principal investigators and visionaries who spearheaded the Bacteraemia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE) trial, Nick Daneman and Rob Fowler (Sunnybrook Health Sciences Centre, Toronto), for a “deep dive into all things that went into this trial” (1). The BALANCE trial spanned over ten years investigating - as the acronym title suggests - whether a shorter treatment duration of seven days was non-inferior to the standard of care of fourteen days for bacteraemia. The conversation covers everything from the initial hallway discussions that sparked the trial to the trial itself that screened over 36,000 patients and enrolled +3,600, its key takeaways and its impact on clinical practice as well as what's next for Daneman and Fowler.This episode was edited by Kathryn Hostettler and Megan Klatt, and peer reviewed by Dr. Arjana Zerja of Mother Theresa University Hospital Centre, Tirana, Albania.Related podcast episodesCommunicable episode 36: Finding BALANCE in antibiotic durations—the BALANCE trial https://share.transistor.fm/s/b680895eCommunicable episode 26: SNAP out of it—rethinking anti-staphylococcal penicillins for S. aureus bacteremia, the SNAP trial PSSA/MSSA results https://share.transistor.fm/s/2a3c3bb4Breakpoints episode covering IDWeek (December 2024) https://breakpoints-sidp.org/108-idweek-2024-recap-late-breaker-abstracts-and-stewardship-talks/ ReferencesBALANCE Investigators, et al.  Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections. N Engl J Med. 2025 March. DOI: 10.1056/NEJMoa2404991Further reading Fowler VG. Eight days a week – BALANCING duration and efficacy. N Engl J Med. 2025 March. DOI: 10.1056/NEJMe2414037   Dulhunty JM, et al. Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial. JAMA 2024. DOI: 10.1001/jama.2024.9779  Yahav D, et al. Seven versus 14 days of antibiotic therapy for uncomplicated Gram-negative bactermia: A noninferiority randomized controlled trial. Clin Infect Dis 2018. DOI: 10.1093/cid/ciy1054 Von Dach E, et al. Effect of C-reactive protein-guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated Gram-negative bacteremia, a randomized clinical trial. JAMA 2020. DOI: 10.1001/jama.2020.6348 Ong SWX, et al. Identifying heterogeneity of treatment effect for antibiotic duration in bloodstream infection: an exploratory post-hoc analysis of the BALANCE randomised clinical trial. EClinicalMedicine 2025. DOI: 10.1016/j.eclinm.2025.103195Wallach JD, et al. Evaluation of evidence of statistical support and corroboration of subgroup claims in randomized clinical trials. JAMA Intern Med 2017. DOI: 10.1001/jamainternmed.20169125

Doi membri ai Senatului au refuzat să se ridice în picioare la momentul de reculegere cerut de grupul AUR. Una dintre ei, senatoarea PSD Victoria Stoiciu, a venit în emisiunea „Decriptaj” alături de experta în comunicare Oana Marinescu. Discutăm despre pericolul alunecării Americii în violență politică și autoritarism, precum și despre efectele asupra României.

BUFFALO, NY — September 18, 2025 — A new #research paper was #published in Volume 17, Issue 8 of Aging-US on August 9, 2025, titled “The myokine FGF21 associates with enhanced survival in ALS and mitigates stress-induced cytotoxicity.” In this study, led by first author Abhishek Guha and corresponding author Peter H. King from the University of Alabama at Birmingham and the Birmingham Veterans Affairs Medical Center, researchers discovered that a hormone called FGF21, which is released by muscles, is elevated in people with amyotrophic lateral sclerosis (ALS) and may play a protective role. These findings are especially relevant because ALS is a fatal and currently incurable neurodegenerative disease. Amyotrophic lateral sclerosis is an age-related and progressive condition that affects the nerve cells responsible for muscle control. While some treatments can slow the disease, there is still a need to understand why ALS progresses at different rates in different individuals. “In a prior muscle miRNA sequencing investigation, we identified altered FGF pathways in ALS muscle, leading us to investigate FGF21.” The research team analyzed muscle biopsies, spinal cord tissue, and blood samples from ALS patients and found that FGF21 levels were significantly elevated. This increase was particularly evident in atrophied muscle fibers—those that had shrunk due to nerve loss—and in the surrounding tissue. Importantly, patients with higher plasma levels of FGF21 showed slower loss of function and longer survival, with some living more than six years after diagnosis. Using animal models and cultured cells, the researchers demonstrated that FGF21 levels rise even in the early, symptom-free stages of ALS. The hormone appeared to protect both muscle and motor neurons from stress-related damage. When added to stressed cells, FGF21 improved cell survival and reduced markers of cell death. In human muscle cells, FGF21 also supported the formation of new muscle fibers, a process known as myogenesis. Blood tests revealed that patients with higher levels of FGF21 not only experienced slower disease progression but also tended to have a higher body mass index (BMI), a factor previously associated with longer survival in ALS. This suggests that FGF21 may reflect a patient's ability to counteract ALS through natural protective mechanisms. It could also serve as a biomarker to monitor disease severity and potentially guide treatment decisions. The study also investigated how FGF21 communicates with cells. It found that the hormone's activity depends on a protein called β-Klotho, which was also altered in ALS-affected tissues. These changes were especially noticeable in motor neurons and muscle cells under stress, further highlighting FGF21's role in the body's response to damage. While the study does not show that FGF21 can be used as a treatment, it highlights the hormone as a promising target for future research, clinical trials, and strategies to slow ALS progression by leveraging the body's natural protective systems. DOI - https://doi.org/10.18632/aging.206298 Corresponding author - Peter H. King - phking@uabmc.edu Abstract video - https://www.youtube.com/watch?v=zEGMxQrxZxE Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, fibroblast growth factor, 21 β-Klotho, ALS biomarker, human skeletal muscle, motor neurons To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Welcome to the Mind Muscle Connection Podcast!You've dropped your calories, tracked everything, and trained hard but the scale's not budging. In this solo episode, I talk about Not losing fat after 30? Here's why and what to doI walk through the three most common reasons people get stuck, including why pushing harder or clinging to your lowest weight might be making things worse, how to use low calories strategically, and when it's time to shift into maintenance.If you've been doing all the right things but still not seeing progress, this episode is worth your time.Let's talk about:IntroductionReasons you're not losing fatWhy pushing through low weight can backfireLow caloriesShifting into Maintenance/BuildingFollow me on Instagram for more information and education:  jeffhoehn_FREE 30 Min Strategy Call: HEREBody Recomp Masterclass: HERENutrition Periodization Masterclass: HEREHow You Can Work With Me?: HERECoaching application: HEREBody Recomp Checklist 2.0: https://chipper-producer-6244.kit.com/26b5c9f94a

Parvenir à insuffler la vie aux objets est un très vieux rêve de l'humanité. Depuis la Préhistoire, les humains sont capables de reproduire et de recopier fidèlement ce qu'ils voient avec la peinture ou la sculpture, parfois même en profitant de formes naturelles évocatrices . Script: Sigi de la chaîne L'Opératorium @LOperatorium https://www.youtube.com/channel/UCQsRUy57omVJVI6Vxv0cuew Adhérez à cette chaîne pour obtenir des avantages : https://www.youtube.com/channel/UCN4TCCaX-gqBNkrUqXdgGRA/join Pour soutenir la chaîne, au choix: 1. Cliquez sur le bouton « Adhérer » sous la vidéo. 2. Patreon: https://www.patreon.com/hndl 00:00 Introduction 03:15 Mécanique hydraulique 12:54 Horlogerie et automates mécaniques 18:26 Androïdes 22:14 Conclusion Abonnez-vous à ma chaine: https://www.youtube.com/c/LHistoirenousledira Instagram: https://www.instagram.com/laurentturcot Musique issue du site : https://epidemicsound.com Images provenant de https://www.storyblocks.com Les vidéos sont utilisées à des fins éducatives selon l'article 107 du Copyright Act de 1976 sur le Fair-Use. Sources et pour aller plus loin: Christian Bailly, L'Âge d'Or des Automates, 1848-1914 (Ars Mundi, 1991 réédition de 1987) Alfred Chapuis et Edmond Droz, Les Automates (Editions du Griffon, 1949) Hélène Fragaki, "Automates et statues merveilleuses dans l'Alexandrie antique" Journal des Savants (2012), pp. 29-67. https://www.persee.fr/doc/jds_0021-8103_2012_num_1_1_6293 Alexis Kugel, Un Bestiaire mécanique. Horloges à automates de la Renaissance, 1580-1640, Editions Monelle Hayot et Galerie J. Kugel, 2016. Lebrère, Marylène. “L'artialisation Des Sons de La Nature Dans Les Sanctuaires à Automates d'Alexandrie, Du IIIe s. Av. J.-C. Au Ier s. Apr. J.-C.” Pallas, no. 98, 2015, pp. 31–53, http://www.jstor.org/stable/43606227. Rabeyroux Anne. "Images de la « merveille » : la « Chambre de Beautés »" Médiévales, n°22-23, 1992. DOI : https://doi.org/10.3406/medi.1992.1238 Jane Irwin, Nisi Shawl, “Clockwork Game: The Illustrious Career of a ChessPlaying Automaton”, Fiery Studios, Illustrated edition, May 6, 2014. Joanne Pillsbury, (6 novembre 2015) “Modeling the World: Ancient Architectural Models Now on View” Met Museum (Blogue) https://www.metmuseum.org/blogs/now-at-the-met/2015/modeling-the-world-ancient-architectural-models Susan Fourtané (31 août 2018) “The Turk: Wolfgang von Kempelen's Fake Automaton Chess Player” Interesting Engineering https://interestingengineering.com/the-turk-fake-automaton-chess-player Kat Eschner (20 juillet 2017) “Debunking the Mechanical Turk Helped Set Edgar Allan Poe on the Path to Mystery Writing” Smithonian Mag https://www.smithsonianmag.com/smart-news/debunking-mechanical-turk-helped-set-edgar-allan-poe-path-mystery-writing-180964059/? Marielle Brie (29 mai 2020) "Histoire des automates : androïdes et animaux" Sciences et médecine, outils techniques https://www.mariellebrie.com/histoire-des-automates-androides-et-animaux/ "Automates Jaquet-Droz" Wikipédia (FR) https://fr.wikipedia.org/wiki/Automates_Jaquet-Droz Jane Irwin et Nisi Shawl, Clockwork Game: The Illustrious Career of a ChessPlaying. Illustrated Edition (Fiery Studios, 2014) "Model Cattle stable from the tomb of Meketre | Middle Kingdom", The Metropolitan Museum of Art https://www.metmuseum.org/art/collection/search/544254?fbclid=IwAR10Zu4rB_WpUJyYxahJ3h8zwX9Gq-SBITfh3PgzB6rq-ntXGfs1vu5MC_Y "125 ap. J.-C. Les automates de Héron d'Alexandrie", Atelier Canopé 95 https://atelier-canope95.canoprof.fr/eleve/Automates%20et%20robots/res/robot.dossierHtml/co/04heronDalexandrie_2.html "Heronis Alexandrini Spiritalium Liber", Gallica BnF https://gallica.bnf.fr/ark:/12148/bpt6k1522249g/f60.item.r=HERONIS%20ALEXANDRINI%20SPIRITALIUM%20LIBER "Démonstrations publiques des automates Jaquet-Droz" MySwitzerland https://www.myswitzerland.com/de/erlebnisse/veranstaltungen/demonstrations-publiques-des-automates-jaquet-droz/#:~:text=Les%20trois%20automates%20sont%20parfaitement,lointains%20anc%C3%AAtres%20des%20robots%20modernes. Images: https://www.musees.strasbourg.eu/oeuvre-musee-des-arts-decoratifs/-/entity/id/318051 https://www.britishmuseum.org/collection/object/H_1958-1006-3048 (image) https://westfalen.museum-digital.de/singleimage?imagenr=270 (image) https://www.ambrosiana.it/scopri/collezioni/?filter_by=autore&term=da-vinci (image) http://www.codex-atlanticus.it./#/Overview Reconstitution dans 4 films en noir et blanc (automaton cinema preview site Todd Karr): https://www.youtube.com/watch?v=Y_PSC25NP68 Le texte et Les Sources ont été vérifiés de manière indépendante par un historien PhD. Autres références disponibles sur demande. #histoire #documentaire #automates #droides #robot

C'est une des choses les plus naturelle du monde, suer. Pourtant, toutes les sueurs ne se valent pas. Adhérez à cette chaîne pour obtenir des avantages : https://www.youtube.com/channel/UCN4TCCaX-gqBNkrUqXdgGRA/join Pour soutenir la chaîne, au choix: 1. Cliquez sur le bouton « Adhérer » sous la vidéo. 2. Patreon: https://www.patreon.com/hndl Musique issue du site : epidemicsound.com Images provenant de https://www.storyblocks.com Abonnez-vous à la chaine: https://www.youtube.com/c/LHistoirenousledira 00:00:00 - Introduction 00:01:11 - La sueur dans l'histoire 00:01:31 - Pour faire une histoire courte... 00:02:57 - Grèce antique 00:05:03 - Rome antique 00:05:46 - Moyen Âge 00:08:00 - Renaissance 00:08:16 - 17e et 18e siècles 00:10:14 - 19e siècle 00:13:57 - 20e siècle 00:16:13 - La sueur dans la période de l'après-guerre 00:17:57 - Sur les réseaux sociaux 00:18:07 - Conclusion Les vidéos sont utilisées à des fins éducatives selon l'article 107 du Copyright Act de 1976 sur le Fair-Use. Sources et pour aller plus loin: E.T. Renbourn, « The History of Sweat and the Sweat Rash From Earliest Times of the End of the 18th Century », Journal of the History of Medicine and Allied Sciences, Volume XIV, Issue 4, April 1959, Pages 202–227, https://doi.org/10.1093/jhmas/XIV.4.202 E.T. Renbourn, « The history of sweat and prickly heat, 19th-20th Century », The Journal of Investigative Dermatology, Vol. 30, no 5, may 1958. Alain Corbin, Le Miasme et la jonquille : l'odorat et l'imaginaire social, XVIIIe – XIXe siècles, Paris, Flammarion, 1982. Sarah Everts, The Joy Of Sweat: The Strange Science of Perspiration. W. W. Norton, 2021. Sarah Everts, « How Advertisers Convinced Americans They Smelled Bad ». Smithsonian Magazine. 2 août 2012. https://www.smithsonianmag.com/history/how-advertisers-convinced-americans-they-smelled-bad-12552404/ Bill Hayes, Sweat: A History of Exercise, Bloomsbury, 2022. Georges Vigarello, Le Propre et le sale, l'hygiène du corps depuis le Moyen Age, Seuil, 2013 Robert Muchembled, La civilisation des odeurs, Paris, Belles Lettres, 2017 Jean-Alexandre Perras et Érika Wicky, « La sémiologie des odeurs au XIXe siècle : du savoir médical à la norme sociale », Éditions françaises, Volume 49, numéro 3, 2014 Gérard Seignan, « L'hygiène sociale au XIXe siècle : une physiologie morale », Revue d'histoire du 19è siècle, 40 / 2010, 113-130 https://doi.org/10.4000/rh19.3996 Jacalyn Duffin, « Sweating blood: history and review », CMAJ 2017 October 23;189:E1315-7. doi: 10.1503/cmaj.170756 Jean-Claude Le Joliff, « Petite histoire du déodorant », La Cosmétothèque, 2 décembre 2022. https://cosmetotheque.com/2022/12/02/petite-histoire-du-deodorant/ « A brief history of body odor », The Week. 27 mars 2016. https://theweek.com/articles/614722/brief-history-body-odor Gilles Raveneau, « Suer. Traitements matériels et symboliques de la transpiration », Ethnologie française, 2011/1 (Vol. 41), p. 49-57. DOI : 10.3917/ethn.111.0049. URL : https://www.cairn.info/revue-ethnologie-francaise-2011-1-page-49.htm Gilles Vandal, « Les épidémies de suette anglaise de 1485-1551 », La Tribune, 24 juin 2020. https://www.latribune.ca/2020/06/24/les-epidemies-de-suette-anglaise-de-1485-1551-1d0e1aad01a0fb46f76cfcdabe7696b2/ Stefene Russel, « A brief history of sweating in America », Historiola !, 17 juillet 2023. https://historiola.substack.com/p/a-brief-history-of-sweating-in-america Hunter Oatman-Stanford, « Our Pungent History: Sweat, Perfume, and the Scent of Death », CW Collectors Weekly, 8 mars 2016. https://www.collectorsweekly.com/articles/our-pungent-history/ La grande histoire de la sudation, Radio Panik, 2 juillet 2019. https://www.radiopanik.org/emissions/pbg/la-grande-histoire-de-la-sudation/ 'Sweat: A History of Exercise' with author Bill Hayes | The Drum https://www.youtube.com/watch?v=aqeehQ-vME0 « The History of Commercial Deodorants ». s. d. ThoughtCo. https://www.thoughtco.com/history-of-commercial-deodorants-1991570 Maurizio Meloni, « Porous Bodies: Environmental Biopower and the Politics of Life in Ancient Rome », Theory, Culture & Society, Vol. 38, Issue 3, 2020. https://journals.sagepub.com/doi/10.1177/0263276420923727 « Perspiration », Wikipédia https://en.wikipedia.org/wiki/Perspiration « Sweating sickness », Wikipédia https://en.wikipedia.org/wiki/Sweating_sickness Senneville, Gabriel. 2018. « Un peu d'histoire: Une histoire sociale des odeurs ». Zone Campus (blog). 23 mars 2018. https://zonecampus.ca/un-peu-dhistoire-une-histoire-sociale-des- odeurs/. « The History of Commercial Deodorants ». ThoughtCo. 25 mars 2019. https://www.thoughtco.com/history-of-commercial-deodorants-1991570 Autres références disponibles sur demande. #histoire #documentaire #sueur #culture #santé #sports #sweat #perspiration #deodorant

BUFFALO, NY — September 16, 2025 — A new #research paper was #published in Volume 17, Issue 8 of Aging-US on August 6, 2025, titled “Age-related trends in amyloid positivity in Parkinson's disease without dementia.” In this study, led by first author Keiko Hatano and corresponding author Masashi Kameyama from the Tokyo Metropolitan Institute for Geriatrics and Gerontology in Japan, researchers found that patients with Parkinson's disease (PD) diagnosed in their 80s showed a significantly higher rate of amyloid positivity—an indicator associated with Alzheimer's disease—compared to those diagnosed at a younger age. Importantly, none of the participants had dementia. These findings suggest that older patients with PD may face a greater risk of future cognitive decline and could benefit from early screening for Alzheimer's-related brain changes. Amyloid-beta is considered a key marker of cognitive decline. While it is known that amyloid accumulation contributes to PD with dementia, its role in patients who have not developed cognitive problems remains less understood. This study aimed to explore how age influences amyloid buildup in people with PD who do not yet show signs of dementia. The researchers analyzed data from 89 individuals with PD and no signs of dementia. Participants were divided into two age-based groups: those diagnosed before age 73 (LOW group) and those diagnosed at age 73 or older (HIGH group). Using cerebrospinal fluid samples, they measured levels of amyloid-beta, a standard method for detecting early Alzheimer's-related changes. The findings revealed that 30.6% of the older group tested positive for amyloid, compared to just 10.0% in the younger group. “[…] we elucidated the prevalence of amyloid positivity in patients with PD without dementia, whose mean age at diagnosis was 80.2 years, using CSF Aβ42 levels.” Interestingly, both age groups of Parkinson's patients had a lower rate of amyloid positivity than cognitively normal individuals of the same age in the general population. This unexpected result suggests that PD may alter how amyloid accumulates in the brain, possibly shortening the phase in which amyloid builds up silently before symptoms appear. The authors suggest that amyloid buildup could accelerate the transition from healthy cognition to dementia in patients with PD. The study also observed age-related associations with other biological markers of Alzheimer's disease, such as tau protein levels. As the global population continues to age and the number of older adults diagnosed with PD grows, identifying early warning signs of cognitive decline becomes increasingly important. These findings may help inform future screening approaches and support the development of therapies aimed at delaying or preventing dementia in people with Parkinson's disease. DOI - https://doi.org/10.18632/aging.206297 Corresponding author - Masashi Kameyama - kame-tky@umin.ac.jp Abstract video - https://www.youtube.com/watch?v=AP8S9evzCJw Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206297 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, amyloid positivity, Parkinson's disease without dementia, cerebrospinal fluid Aβ42 To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-450 Overview: Use of e-cigarettes has increased significantly over the last several years and their popularity continues to grow, notably among adolescents and young adults. Recent evidence indicates that the majority of teens and young adults who vape consider quitting; however, nicotine addiction has historically been difficult to treat in this population. Join us as we discuss the prevalence of vaping, associated harms, and new evidence on the effectiveness of varenicline on cessation.  Episode resource links: CDC https://www.cdc.gov/tobacco/e-cigarettes/youth.html Evins, A. E., Cather, C., Reeder, H. T., Evohr, B., Potter, K., Pachas, G. N., Gray, K. M., Levy, S., Rigotti, N. A., Iroegbulem, V., Dufour, J., Casottana, K., Costello, M. A., Gilman, J. M., & Schuster, R. M. (2025). Varenicline for Youth Nicotine Vaping Cessation: A Randomized Clinical Trial. JAMA, e253810. Advance online publication. https://doi.org/10.1001/jama.2025.3810 Lindson N, Butler AR, McRobbie H, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. 2024;1(1):CD010216. Published 2024 Jan 8. doi:10.1002/14651858.CD010216.pub8 Park-Lee E, Ren C, Sawdey MD, et al. Notes from the Field: E-Cigarette Use Among Middle and High School Students — National Youth Tobacco Survey, United States, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1387–1389. DOI: http://dx.doi.org/10.15585/mmwr.mm7039a4external icon;  Tuisku A, Rahkola M, Nieminen P, Toljamo T. Electronic Cigarettes vs Varenicline for Smoking Cessation in Adults: A Randomized Clinical Trial. JAMA Intern Med. 2024;184(8):915–921. doi:10.1001/jamainternmed.2024.1822 Zhang, L., Gentzke, A., Trivers, K. F., & VanFrank, B. (2022). Tobacco Cessation Behaviors Among U.S. Middle and High School Students, 2020. The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 70(1), 147–154. https://doi.org/10.1016/j.jadohealth.2021.07.011 Guest: Susan Feeney, DNP, FNP-BC, NP-C Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-450 Overview: Use of e-cigarettes has increased significantly over the last several years and their popularity continues to grow, notably among adolescents and young adults. Recent evidence indicates that the majority of teens and young adults who vape consider quitting; however, nicotine addiction has historically been difficult to treat in this population. Join us as we discuss the prevalence of vaping, associated harms, and new evidence on the effectiveness of varenicline on cessation.  Episode resource links: CDC https://www.cdc.gov/tobacco/e-cigarettes/youth.html Evins, A. E., Cather, C., Reeder, H. T., Evohr, B., Potter, K., Pachas, G. N., Gray, K. M., Levy, S., Rigotti, N. A., Iroegbulem, V., Dufour, J., Casottana, K., Costello, M. A., Gilman, J. M., & Schuster, R. M. (2025). Varenicline for Youth Nicotine Vaping Cessation: A Randomized Clinical Trial. JAMA, e253810. Advance online publication. https://doi.org/10.1001/jama.2025.3810 Lindson N, Butler AR, McRobbie H, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. 2024;1(1):CD010216. Published 2024 Jan 8. doi:10.1002/14651858.CD010216.pub8 Park-Lee E, Ren C, Sawdey MD, et al. Notes from the Field: E-Cigarette Use Among Middle and High School Students — National Youth Tobacco Survey, United States, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1387–1389. DOI: http://dx.doi.org/10.15585/mmwr.mm7039a4external icon;  Tuisku A, Rahkola M, Nieminen P, Toljamo T. Electronic Cigarettes vs Varenicline for Smoking Cessation in Adults: A Randomized Clinical Trial. JAMA Intern Med. 2024;184(8):915–921. doi:10.1001/jamainternmed.2024.1822 Zhang, L., Gentzke, A., Trivers, K. F., & VanFrank, B. (2022). Tobacco Cessation Behaviors Among U.S. Middle and High School Students, 2020. The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 70(1), 147–154. https://doi.org/10.1016/j.jadohealth.2021.07.011 Guest: Susan Feeney, DNP, FNP-BC, NP-C Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

BUFFALO, NY — September 11, 2025 — A new #research paper was #published in Volume 17, Issue 8 of Aging-US on August 8, 2025, titled “AI-driven toolset for IPF and aging research associates lung fibrosis with accelerated aging.” In this study, researchers Fedor Galkin, Shan Chen, Alex Aliper, Alex Zhavoronkov, and Feng Ren from Insilico Medicine used artificial intelligence (AI) to investigate the similarities between idiopathic pulmonary fibrosis (IPF), a severe lung disease, and the aging process. Their findings show that IPF is not simply accelerated aging, but a distinct biological condition shaped by age-related dysfunction. This insight may lead to a new approach in how scientists and clinicians treat this complex disease. IPF mainly affects individuals over the age of 60. It causes scarring of lung tissue, making it harder to breathe and often leading to respiratory failure. Current treatments can slow the disease but rarely stop or reverse its progression. The researchers used AI to identify shared biological features between aging and fibrosis, finding new potential targets for therapy. The team developed a “proteomic aging clock” based on protein data from more than 55,000 participants in the UK Biobank. This AI-driven tool accurately measured biological age and found that patients with severe COVID-19, who are at increased risk for lung fibrosis, also showed signs of accelerated aging. This suggests that fibrosis leaves a detectable biological trace, supporting the use of aging clocks in studying age-related diseases. “For aging clock training, we used the UK Biobank collection of 55319 proteomic Olink NPX profiles annotated with age and gender.” They also developed a custom AI model, ipf-P3GPT, to compare gene activity in aging lungs versus those with IPF. Although some genes were active in both, many showed opposite behavior. In fact, more than half of the shared genes had inverse effects. This means IPF does not just speed up aging but also disrupts the body's normal aging pathways. The study identified unique molecular signatures that distinguish IPF from normal aging. While both involve inflammation and tissue remodeling, IPF drives more damaging changes to lung structure and repair systems. This difference could guide the development of drugs that specifically target fibrosis without affecting normal aging. By combining AI with large-scale biological data, the study also introduces a powerful toolset for examining other age-related conditions such as liver and kidney fibrosis. These models may support personalized treatments and expand understanding of the relationships between aging and disease, opening new directions for therapy development. DOI - https://doi.org/10.18632/aging.206295 Corresponding author - Alex Zhavoronkov - alex@insilico.com Abstract video - https://www.youtube.com/watch?v=24lX2lHbt7o Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206295 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, IPF, generative AI, transformer, proteomics To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Husband-and-wife team William Firth Wells and Mildred Weeks Wells conducted research that had the potential to make a big difference in the safety of indoor air. But it didn’t really have a significant impact on public health. Research: Associated Press. “Super-Oyster Is On its Way to Dinner Table Bigger and Better Bivalve Sports Pedigree.” 3/13/1927. https://www.loc.gov/resource/sn84020064/1927-03-13/ed-1/?sp=14 “Brought Back to Texas.” The Houston Semi-Weekly Post. 12/26/1889. https://www.newspapers.com/image/1196039760/ Decatur Daily Review. “Scientists Fight Flu Germs with Violet Ray.” 7/30/1936. https://www.newspapers.com/image/94335504/ Evening Star. “Scientific Trap-shooter.” 6/26/1937. https://www.loc.gov/resource/sn83045462/1937-06-26/ed-1/?sp=7&q=William+Firth+Wells&r=0.668,0.557,0.438,0.158,0 Fair, Gordon M. and William Weeks Wells. “Method and Apparatus for Preventing Infection.” U.S. Patent 2,198,867. https://ppubs.uspto.gov/api/pdf/downloadPdf/2198867 Hall, Dominic. “New Center for the History of Medicine Artifact - Wells Air Centrifuge.” Harvard Countway Library. https://countway.harvard.edu/news/new-center-history-medicine-artifact-wells-air-centrifuge “Incubator Is Now Oyster Nurse.” Washington Times. 10/1/1925. https://www.loc.gov/resource/sn84026749/1925-10-01/ed-1/?sp=12 Lewis, Carol Sutton. “Mildred Weeks Wells’s Work on Airborne Transmission Could Have Saved Many Lives—If the Scientific Establishment Listened.” Lost Women of Science Podcast. Scientific American. 5/22/2025. https://www.scientificamerican.com/article/a-public-health-researcher-and-her-engineer-husband-found-how-diseases-can/ Library and Archives Team. “William Firth Wells and Mildred Weeks Wells.” Washington College. https://www.washcoll.edu/people_departments/offices/miller-library/archives-special-collections/archives-blog/Wells%20papers.php Molenti, Megan. “The 60-Year-Old Scientific Screwup That Helped Covid Kill.” Wired. 5/13/2021. https://www.wired.com/story/the-teeny-tiny-scientific-screwup-that-helped-covid-kill/ Perkins JE, Bahlke AM, Silverman HF. Effect of Ultra-violet Irradiation of Classrooms on Spread of Measles in Large Rural Central Schools Preliminary Report. Am J Public Health Nations Health. 1947 May;37(5):529-37. PMID: 18016521; PMCID: PMC1623610. Randall, Katherine and Ewing, E. Thomas and Marr, Linsey and Jimenez, Jose and Bourouiba, Lydia, How Did We Get Here: What Are Droplets and Aerosols and How Far Do They Go? A Historical Perspective on the Transmission of Respiratory Infectious Diseases (April 15, 2021). Available at SSRN: https://ssrn.com/abstract=3829873 Riley, Richard L. “What Nobody Needs to Know About Airborne Infection.” American Journal of Respiratory and Critical Care Medicine. Volume 163, Issue 1. https://www.atsjournals.org/doi/10.1164/ajrccm.163.1.hh11-00 Simon, Clea. “Did a socially awkward scientist set back airborne disease control?” The Harvard Gazette. 3/7/2025. https://news.harvard.edu/gazette/story/2025/03/did-a-socially-awkward-scientist-set-back-airborne-disease-control/ “Texas State News.” McKinney Weekly Democrat-Gazette. 4/17/1890. https://www.newspapers.com/image/65385350/ WELLS MW, HOLLA WA. VENTILATION IN THE FLOW OF MEASLES AND CHICKENPOX THROUGH A COMMUNITY: Progress Report, Jan. 1, 1946 to June 15, 1949, Airborne Infection Study, Westchester County Department of Health. JAMA. 1950;142(17):1337–1344. doi:10.1001/jama.1950.02910350007004 WELLS MW. VENTILATION IN THE SPREAD OF CHICKENPOX AND MEASLES WITHIN SCHOOL ROOMS. JAMA. 1945;129(3):197–200. doi:10.1001/jama.1945.02860370019006 WELLS WF, WELLS MW. AIR-BORNE INFECTION. JAMA. 1936;107(21):1698–1703. doi:10.1001/jama.1936.02770470016004 WELLS WF, WELLS MW. AIR-BORNE INFECTION: SANITARY CONTROL. JAMA. 1936;107(22):1805–1809. doi:10.1001/jama.1936.02770480037010 Wells, W F, and M W Wells. “Measurement of Sanitary Ventilation.” American journal of public health and the nation's health vol. 28,3 (1938): 343-50. doi:10.2105/ajph.28.3.343 Wells, William Firth and Gordon Maskew Fair. Viability of B. coli Exposed to Ultra-Violet Radiation in Air.Science82,280-281(1935).DOI:10.1126/science.82.2125.280.b Wells, William Firth and Mildred Weeks Wells. Measurement of Sanitary Ventilation American Journal of Public Health and the Nations Health 28, 343_350, https://doi.org/10.2105/AJPH.28.3.343 Zimmer, Carl. “Air-Borne: The Hidden History of the Life We Breathe.” Dutton. 2025. See omnystudio.com/listener for privacy information.

In this BTP Short, Dr. Dewey Caron shares another of his “audio postcards,” this time exploring the critical role of fat bees—also known as diutinus bees—in helping colonies survive winter. Dewey explains how these long-lived worker bees differ from their summer sisters, with enlarged fat bodies, higher protein reserves, and lower juvenile hormone levels, all tied to the key blood protein vitellogenin. Drawing on published research papers, Dewey highlights how environmental cues such as declining pollen, temperature, and daylight trigger the production of winter bees, and how clustering helps colonies thermoregulate through the cold months. He emphasizes that strong, heavy colonies going into winter are far more likely to survive than weak or light ones. For beekeepers, Dewey stresses the importance of continuous Varroa control throughout the season, fall feeding to ensure sufficient carbohydrate and protein stores, and combining weaker units when necessary. He also discusses drone eviction, stock influences, and climate change modeling that suggests warmer falls may disrupt the balance of winter bee production and survival. This episode provides science-based insights and practical recommendations to help beekeepers communicate with their colonies—ensuring not only fat bees, but fat, well-prepared colonies for overwintering success. Websites and Links mention in the episode: Döke, Mehmet A. M. Frazier, and C.  Grozinger, 2015 “Overwintering honey bees: biology and management,” Current Opinion in Insect Science. Mehmet Ali Döke, Christina M. Grozinger. 2017. Pheromonal control of overwintering physiology and success in honey bees (Apis mellifera, L.) Döke, Mehmet Ali, CM McGrady, M. Otieno, CM Grozinger, M Frazier. 2019. Colony size, rather than geographic origin of stocks, predicts overwintering success in honey bees (Hymenoptera: Apidae) in the Northeastern United States. J. Econ. Entomology 112 (2), 525-533, DOI: 10.1093/jee/toy377 Stephanie Feliciano-Cardona, †Mehmet Ali Döke, Janpierre Ale man,Jose Luis Agosto-Rivera. Christina M. Grozinger and Tugrul Giray 2020. Honey Bees in the Tropics Show Winter Bee-Like Longevity in Response to Seasonal Dearth and Brood Reduction. Front. Ecol. Evol., 8.  https://doi.org/10.3389/fevo.2020.571094 Somerville, Doug (2005) Fat Bees Skinny Bees, A manual on honey bee nutrition for beekeepers., Australia. Available on the Web at https://www.agrifutures.com.au/wp-content/uploads/publications/05-054.pdf   https://rirdc.infoservices.com.au/downloads/05-054 Kirti Rajagopalan, Gloria DeGrandi-Hoffman, Matthew Pruett, Vincent P. Jones, Vanessa Corby-Harris, Julien Pireaud, Robert Curry, Brandon Hopkins & Tobin D. Northfield. 2024. Warmer autumns and winters could reduce honey bee overwintering survival with potential risks for pollination services. Scientific Reports volume 14, Article number: 5410 (2024) For homework Ashley L. St. Clair , Nathanael J. Beach, Adam G. Dolezal. 2022.  Honey bee hive covers reduce food consumption and colony mortality during overwintering. Plos One. https://doi.org/10.1371/journal.pone.0266219  SBGM videos:  https://mail.google.com/mail/u/0/#inbox/FMfcgzQcpKmXBhglCpthGSBzvHVLlSfp   Brought to you by Betterbee – your partners in better beekeeping. ______________ Betterbee is the presenting sponsor of Beekeeping Today Podcast. Betterbee's mission is to support every beekeeper with excellent customer service, continued education and quality equipment. From their colorful and informative catalog to their support of beekeeper educational activities, including this podcast series, Betterbee truly is Beekeepers Serving Beekeepers. See for yourself at www.betterbee.com Copyright © 2025 by Growing Planet Media, LLC

Toads continue to amaze us - this time they are using their sense of the Earth's magnetic field to find their way home. But how important this sense is for cane toads as they travel home from long journeys, and how much are they relying on their sense of smell, was a mystery, until a clever new study tested the toads. Then we briefly touch on how pythons digest bones so successfully. Main Paper References: Fernandez RC, Sotelo MI. 2025. A toad's journey home: towards elucidating the neural and sensory basis of amphibian navigation. Proceedings of the Royal Society B: Biological Sciences 292. DOI: 10.1098/rspb.2025.0525. Shaykevich DA, Pareja-Mejía D, Golde C, Pašukonis A, O'Connell LA. 2025. Neural and sensory basis of homing behaviour in the invasive cane toad, Rhinella marina. Proceedings of the Royal Society B: Biological Sciences 292:20250045. DOI: 10.1098/rspb.2025.0045. Other Mentioned Papers/Studies: Lignot J-H, Pope RK, Secor SM. 2025. Diet-dependent production of calcium- and phosphorus-rich ‘spheroids' along the intestine of Burmese pythons: identification of a new cell type? Journal of Experimental Biology 228:jeb249620. DOI: 10.1242/jeb.249620. Other Links/Mentions: Starr M. 2025.New Cell Discovered in Pythons Allows Them to Completely Digest Bones. Available at https://www.sciencealert.com/new-cell-discovered-in-pythons-allows-them-to-completely-digest-bones (accessed August 25, 2025). Editing and Music: Intro/outro – Treehouse by Ed Nelson Species Bi-week theme – Michael Timothy Other Music – The Passion HiFi, https://www.thepassionhifi.com

Welcome to the Olink® Proteomics in Proximity podcast!  Below are some useful resources mentioned in this episode:  Olink tools and software·       Olink® Explore HT, Olink's most advanced solution for high-throughput biomarker discovery, measuring 5400+ proteins simultaneously with a streamlined workflow and industry-leading specificity: https://olink.com/products-services/exploreht/  UK Biobank Pharma Proteomics Project (UKB-PPP), one of the world's largest scientific studies of blood protein biomarkers conducted to date, https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/uk-biobank-launches-one-of-the-largest-scientific-studies  World Health Organization (2003). Adherence to long-term therapies: evidence for action (PDF). Geneva: World Health Organisation. ISBN 978-92-4-154599-0 Research articles and news·       Thermo Fisher Scientific's Olink Platform Selected for World's Largest Human Proteome Studyhttps://ir.thermofisher.com/investors/news-events/news/news-details/2025/Thermo-Fisher-Scientifics-Olink-Platform-Selected-for-Worlds-Largest-Human-Proteome-Study/default.aspx·       Hamilton Se-Hwee Oh et al 2025. Plasma proteomics links brain and immune system aging with healthspan and longevityhttps://www.nature.com/articles/s41591-025-03798-1. Nature Medicine (2025)·       Song, Y., Abuduaini, B., Yang, X. et al. Identification of inflammatory protein biomarkers for predicting the different subtype of adult with tuberculosis: an Olink proteomic study. Inflamm. Res. 74, 60 (2025). https://doi.org/10.1007/s00011-025-02020-9·       Ferhan Qureshi et al 2023. Analytical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis. Proteomics clinical application 2023·       Dhindsa, R.S., Burren, O.S., Sun, B.B. et al. Rare variant associations with plasma protein levels in the UK Biobank. 2023 Nature, DOI: 10.1038/s41586-023-06547-xhttps://www.nature.com/articles/s41586-023-06547-x·       Sun, B.B., Chiou, J., Traylor, M. et al.  Plasma proteomic associations with genetics and health in the UK Biobank. 2023 Nature, DOI: 10.1038/s41586-023-06592-6 https://www.nature.com/articles/s41586-023-06592-6 https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehac495/6676779·       Eldjarn GH, et al. Large-scale plasma proteomics comparisons through genetics and disease associations. Nature. 2023 Oct;622(7982):348-358. doi: 10.1038/s41586-023-06563-xhttps://www.nature.com/articles/s41586-023-06563-x#Sec44·        Carrasco-Zanini et al 2024 Proteomic prediction of common and rare diseases. https://www.nature.com/articles/s41591-024-03142-z . NatureMedicine volume 30,  pages2489–2498 (2024)·       Watanabe K, Wilmanski T, Diener C, et al. Multiomic signatures of body mass index identify heterogeneous health phenotypes and responses to a lifestyle intervention.https://www.nature.com/articles/s41591-023-02248-0·       Petrera A, von Toerne C, Behlr J, et al. Multiplatform Approach for Plasma Proteomics: Complementarity of Olink Proximity Extension Assay Technology to Mass Spectrometry-Based Protein Profiling. (2020) Journal of Proteome Research, https://pubs.acs.org/doi/pdf/10.1021/acs.jproteome.0c00641·       Multicenter Collaborative Study to Optimize Mass Spectrometry Workflows of Clinical Specimens. Kardell O, von Toerne C, Merl-Pham J, König AC, Blindert M, Barth TK, Mergner J, Ludwig C, Tüshaus J, Eckert S, Müller SA, Breimann S, Giesbertz P, Bernhardt AM, Schweizer L, Albrecht V, Teupser D, Imhof A, Kuster B, Lichtenthaler SF, Mann M, Cox J, Hauck SM. J Proteome Res. 2024 Jan 5;23(1):117-129. doi: 10.1021/acs.jproteome.3c00473. Epub 2023 Nov 28. PMID: 38015820 https://pubs.acs.org/doi/10.1021/acs.jproteome.3c00473·       Wei, S., Shen, R., Lu, X. et al. Integrative multi-omics investigation of sleep apnea: gut microbiome metabolomics, proteomics and phenome-wide association study. Nutr Metab (Lond) 22, 57 (2025). https://doi.org/10.1186/s12986-025-00925-0·       Liu, L., Li, M., Qin, Y. et al. Childhood obesity and insulin resistance is correlated with gut microbiome serum protein: an integrated metagenomic and proteomic analysis. Sci Rep 15, 21436 (2025). https://doi.org/10.1038/s41598-025-07357-z·       Zhang, Xiaotao et al.Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial. eBioMedicine, Volume 98, 104873 (2023.).  10.1016/j.ebiom.2023.104873·      &nb...

Lyssa Rome is a speech-language pathologist in the San Francisco Bay Area. She is on staff at the Aphasia Center of California, where she facilitates groups for people with aphasia and their care partners. She owns an LPAA-focused private practice and specializes in working with people with neurogenic communication disorders. She has worked in acute hospital, skilled nursing, and continuum of care settings. Prior to becoming an SLP, Lyssa was a public radio journalist, editor, and podcast producer. In this episode, Lyssa Rome interviews Liz Hoover about group treatment for aphasia.   Guest info Dr. Liz Hoover is a clinical professor of speech language and hearing sciences and the clinical director of the Aphasia Resource Center at Boston University. She holds board certification from the Academy of Neurologic Communication Disorders and Sciences, or ANCDS, and is an ASHA fellow. She was selected as a 2024 Tavistock Trust for Aphasia Distinguished Scholar, USA and Canada. Liz was a founding member of Aphasia Access and served on the board for several years. She has 30 years of experience working with people with aphasia and other communication disorders across the continuum of care. She's contributed to numerous presentations and publications, and most of her work focuses on the effectiveness of group treatment for individuals with aphasia.   Listener Take-aways In today's episode you will: Describe the evidence supporting aphasia conversation groups as an effective interventions for linguistic and psychosocial outcomes. Differentiate the potential benefits of dyads versus larger groups in relation to client goals. Identify how aphasia severity and group composition can influence treatment outcomes.   Edited transcript Lyssa Rome Welcome to the Aphasia Access Aphasia Conversations Podcast. I'm Lyssa Rome. I'm a speech language pathologist on staff at the Aphasia Center of California and I see clients with aphasia and other neurogenic communication disorders in my LPAA-focused private practice. I'm also a member of the Aphasia Access Podcast Working Group. Aphasia Access strives to provide members with information, inspiration and ideas that support their aphasia care through a variety of educational materials and resources.   I'm today's host for an episode that will feature Dr. Elizabeth Hoover, who was selected as a 2024 Tavistock Trust for Aphasia Distinguished Scholar, USA and Canada.   Liz Hoover is a clinical professor of speech language and hearing sciences and the clinical director of the Aphasia Resource Center at Boston University. She holds board certification from the Academy of Neurologic Communication Disorders and Sciences, or ANCDS, and is an ASHA fellow. Liz was a founding member of Aphasia Access and served on the board for several years. She has 30 years of experience working with people with aphasia and other communication disorders across the continuum of care. She's contributed to numerous presentations and publications, and most of her work focuses on the effectiveness of group treatment for individuals with aphasia. Liz, welcome back to the podcast.   So in 2017 you spoke with Ellen Bernstein Ellis about intensive comprehensive aphasia programs or ICAPs and inter professional practice at the Aphasia Resource Center at BU and treatment for verb production using VNest, among other topics. So this time, I thought we could focus on some of your recent research with Gayle DeDe and others on conversation group treatment.   Liz Hoover Sounds good.   Lyssa Rome All right, so my first question is how you became interested in studying group treatment?   Liz Hoover Yeah, I actually have Dr. Jan Avent to thank for my interest in groups. She was my aphasia professor when I was a graduate student doing my masters at Cal State East Bay. As you know, Cal State East Bay is home to the Aphasia Treatment Program. When I was there, it preceded ATP. But I was involved in her cooperative group treatment study, and as a graduate student, I was allowed to facilitate some of her groups in this study, and I was involved in the moderate-to-severe group. She was also incredibly generous at sharing that very early body of work for socially oriented group treatments and exposing us to the work of John Lyons and Audrey Holland. Jan also invited us to go to a conference on group treatment that was run by the Life Link group. It's out of Texas Woman's University, Delaina Walker-Batson and Jean Ford. And it just was a life changing and pivotal experience for me in recognizing how group treatment could not be just an adjunct to individual goals, but actually be the type of treatment that is beneficial for folks with aphasia. So it's been a love my entire career.   Lyssa Rome And now I know you've been studying group treatment in this randomized control trial. This was a collaborative research project, so I'm hoping you can tell us a little bit more about that project. What were your research questions? Tell us a little bit more.   Liz Hoover Yeah, so thank you. I'll just start by acknowledging that the work is funded by two NIDCD grants, and to acknowledge their generosity, and then also acknowledge Dr. Gayle DeDe, who is currently at Temple University. She is a co- main PI in this work, and of course it wouldn't have happened without her. So you know, Gayle and I have known each other for many, many years. She's a former student, doctoral student at Boston University, and by way of background, she and I were interested in working together and interested in trying to build on some evidence for group treatment. I think we drank the Kool Aid early on, as you might say.   And you know, just looking at the literature, there have been two trials on the evidence for this kind of work. And so those of us who are involved in groups, know that it's helpful for people with aphasia, our clients tell us how much they enjoy it, and they vote with their feet, right? In that they come back for more treatments. And aphasia centers have grown dramatically in the last couple of decades in the United States.   So clearly we know they work, but what we don't know is why they work. What are those essential ingredients, and how is that driving the change that we think we see? And from a personal perspective, that's important for me to understand and for us to have explained in the literature, because until we can justify it in the scientific terms, I worry it will forever be a private-pay adjunct that is only accessible to people who can pay for it, or who are lucky enough to be close enough to a center that can get them access—virtual groups aside, and the advent of that—but it's important that I think this intervention is validated to the scientific community in our field.   So we designed this trial. It's a randomized control trial to help build the research evidence for conversation, group treatment, and to also look at the critical components. This was inspired by a paper actually from Nina Simmons Mackie in 2014 and Linda Worrell. They looked at group treatment and showed that there were at least eight first-tier elements that changed the variability or on which we might modify group conversation treatment. And so, you know, if we're all doing things differently, how can we predict the change, and how can we expect outcomes?   Lyssa Rome So I was hoping you could describe this randomized, controlled trial. You know, it was collaborative, and I'm curious about what you and your collaborators had as your research questions.   Liz Hoover So our primary aims of the study were to understand if communication or conversation treatment is associated with changes in measures of communicative ability and psychosocial measures. So that's a general effectiveness question. And then to look in more deeply to see if the group size or the group composition or even the individual profile of the client with aphasia influences the expected outcome.   Because if you think about group treatment, the size of the group is not an insignificant issue, right? So a small group environment of two people has much more… it still gives you some peer support from the other individual with aphasia, but you have many opportunities for conversational turns and linguistic and communication practice and to drive the saliency of the conversation in a direction that's meaningful and useful and informative.   Whereas in a large group environment of say, six to eight people with aphasia and two clinicians, you might see much more influence in the needed social support and vicarious learning and shared lived experience and so forth, and still have some opportunity for communication and linguistic practice. So there's conflicting hypotheses there about which group environment might be better for one individual over another.   And then there's the question of, well, who's in that group with you? Does that matter? Some of the literature says that if you have somebody with a different profile of aphasia, it can set up a therapeutic benefit of the helper experience, where you can gain purpose by enabling and supporting and being a facilitator of somebody else with aphasia.   But if you're in a group environment where your peers have similar conversation goals as you, maybe your practice turns, and your ability to learn vicariously from their conversation turns is greater. So again, two conflicting theories here about what might be best. So we decided to try and manipulate these group environments and measure outcomes on several different communication measures. We selected measures that were linguistic, functional, and psychosocial.   We collected data over four years. The first two years, we enrolled people with all different kinds of profiles of aphasia. The only inclusion criteria from a communication perspective, as you needed some ability to comprehend at a sentence level, so that you could process what was being said by the other people in the group. And in year one, the treatment was at Boston University and Temple University, which is where Gayle's aphasia center is housed. In year two, we added a community site at the Adler Aphasia Center and Maywood, New Jersey, so we had three sites going.   The treatment conditions were dyad, large group, and then a no treatment group. So this group was tested at the same time, didn't get any other intervention, and then we gave them group treatment once the testing cycle was over. So we call that a historical control or a delayed-treatment control group. And then in years three and four, we aim to enroll people who had homogeneous profiles.   So the first through the third cycle was people with moderate to severe profiles. And then in the final, fourth cycle, it was people with mild profiles with aphasia. This allowed us to collect enough data in enough size to be able to look at overall effectiveness and then effects of heterogeneity or homogeneity in the group, and the influence of the profile of aphasia, as well as the group size.   And across the four years, we aim to enroll 216 participants, and 193 completed the study. So it's the largest of its kind for this particular kind of group treatment that we know of anyway. So this data set has allowed us to look at overall efficacy of conversation group treatment, and then also take a look at a couple of those critical ingredients. Does the size of the group make a difference? And does the composition of your group make a difference?   Lyssa Rome And what did you find?   Liz Hoover Well, we're not quite done with all of our analysis yet, but we found overall that there's a significant treatment effect for just the treatment conditions, not the control group. So whether you were in the dyad or whether you were in a large treatment group, you got better on some of the outcome measures we selected. And the control group not only didn't but on a couple of those measures, their performance actually declined. And so showing significantly that there's a treatment effect. Did you have a question?   Lyssa Rome Yeah, I wanted to interrupt and ask, what were the outcome measures? What outcome measures were you looking at?   Liz Hoover Yeah. So we had about 14 measures in total that aligned with the core outcome set that was established by the ROMA group. So we had as our linguistic measure the Comprehensive Aphasia Test. We had a primary outcome measure, which was a patient reported measure of functional communication, which is the ACOM by Will Hula and colleagues, the Aphasia Communication Outcome measure, we had Audrey Holland and colleagues' objective functional measure, the CADL, and then a series of other psychosocial and patient reported outcome measures, so the wall question from the ALA, the Moss Social Scale, the Communication Confidence Rating Scale in Aphasia by Leora Cherney and Edie Babbitt.   Lyssa Rome Thank you. When I interrupted you to ask about outcome measures. You were telling us about some of the findings so far.   Liz Hoover Yeah, so our primary outcome measures showed significant changes in language for both the treatment conditions and a slightly larger effect for the large group. And then we saw, at a more micro level, the results pointing to a complex interaction, actually, between the group size and the treatment outcome. So we saw changes on more linguistic measures. like the repetition sub scores of the CAT and verb naming from another naming subtest for the dyad group, whereas bigger, more robust changes on the ACOM the CADL and the discourse measure from the CAT for the large group.   And then diving in a little bit more deeply for the composition, these data are actually quite interesting. The papers are in review and preparation at the moment, but it looks like we are seeing significant changes for the moderate-to-severe group on objective functional measures and patient reported functional measures of communication, which is so exciting to see for this particular cohort, whose naming scores were zero, in some cases, on entrance, and we're seeing for the mild group, some changes on auditory comprehension, naming, not surprisingly, and also the ACOM and the CADL. So they're showing the same changes, just with different effect sizes or slightly different ranges. And once again, no change in the control group, and in some cases, on some measures, we're seeing a decline in performance over time.   So it's validating that the intervention is helpful in general. What we found with the homogeneous groups is that in a homogeneous large group environment, those groups seem to do a little better. There's a significant effect over time between the homogeneous and the heterogeneous groups. So thinking about why that might have taken place, we wonder if the shared lived experience of your profile of aphasia, your focus on similar kinds of communication, or linguistic targets within the conversation environment might be helping to offset the limited number of practice trials you get in that larger group environment.   So that's an interesting finding to see these differences in who's in the group with you. Because I think clinically, we tend to assign groups, or sort of schedule groups according to what's convenient for the client, what might be pragmatic for the setting, without really wondering why one group could be important or one group might be preferential. If we think about it, there are conflicting hypotheses as to why a group of your like aphasia severity might have a different outcome, right? That idea that you can help people who have a different profile than you, that you're sharing different kinds of models of communication, versus that perhaps more intense practice effect when you share more specific goals and targets and lived experiences. So it's interesting to think about the group environment from that perspective, I think,   Lyssa Rome And to have also some evidence that clinicians and people at aphasia centers can look to help make decisions about group compositions, I think is incredibly helpful.   Earlier, you mentioned that one of the goals of this research project has been to identify the active ingredients of group therapy. And I know that you've been part of a working group for the Rehabilitation Treatment Specification System, or RTSS. Applying that, how have you tried to identify the active ingredients and what? What do you think it is about these treatments that actually drives change?   Liz Hoover I'll first of all say, this is a work in process. You know, I don't think we've got all of the answers. We're just starting to think about it with the idea, again, that if we clinically decide to make some changes to our group, we're at least doing it with some information behind us, and it's a thoughtful and intentional change, as opposed to a gut reaction or a happenstance change. So Gayle and I have worked on developing this image, or this model. It's in a couple of our papers. We can share the resources for that. But it's about trying to think of the flow of communication, group treatment, and what aspects of the treatment might be influential in the outcomes we see downstream.   I think for group treatment, you can't separate entirely many of the ingredients. Group treatment is multifaceted, it's interconnected, and it's not possible—I would heavily debate that with anybody—I don't think it's possible to sort of truly separate some of these ingredients. But when you alter the composition or the environment in which you do the treatment, I do think we are influencing the relative weight of these ingredients.   So we've been thinking about there being this group dynamics component, which is the supportive environment of the peers in the group with you, that social support, the insider affiliation and shared lived experience, the opportunity to observe and see the success of some of these different communication strategies, so that vicarious learning that takes place as you see somebody else practice. But also, I think, cope in a trajectory of your treatment process.   And then we've got linguistic practice so that turn taking where you're actually trying to communicate verbally using supported communication where you're expanding on your utterances or trying to communicate verbally in a specific way or process particular kinds of linguistic targets. A then communication practice in terms of that multimodal effectiveness of communication.   And these then are linked to these three ingredients, dynamic group dynamics, linguistic practice and communication practice. They each have their own mechanism of action or a treatment theory that explains how they might affect change. So for linguistic practice, it's the amount of practice, but also how you hear it practiced or see it practiced with the other group participant. And the same thing for the various multimodal communication acts. And in thinking about a large group versus the dyad or a small group, you know you've got this conflicting hypothesis or the setup for a competing best group, or benefit in that the large group will influence more broadly in the group dynamics, or more deeply in the group dynamics, in that there's a much bigger opportunity to see the vicarious learning and experience the support and potentially experience the communication practice, given a varied number of participants.   But yet in the dyad, your opportunity for linguistic practice is much, much stronger. And our work has counted this the exponential number of turns you get in a dyad versus a large group. And you know, I think that's why the results we saw with the dyad on those linguistic outcomes were unique to that group environment.   Lyssa Rome It points, I think, to the complexity of decision making around group structure and what's right for which client, maybe even so it sounds like some of that work is still in progress. I'm curious about sort of thinking about what you know so far based on this work, what advice would you have for clinicians who are working in aphasia centers or or helping to sort of think about the structure of group treatments? What should clinicians in those roles keep in mind?   Liz Hoover Yeah, that's a great question, and I'll add the caveat that this may change. My advice for this may change in a year's time, or it might evolve as we learn more. But I think what it means is that the decisions you make should be thoughtful. We're starting to learn more about severity in aphasia and how that influences the outcomes. So I think, what is it that your client wants to get out of the group? If they're interested in more linguistic changes, then perhaps the dyad is a better place to start. If they clearly need, or are voicing the need, for more psychosocial support, then the large, you know, traditional sized and perhaps a homogeneous group is the right place to start. But they're both more effective than no treatment. And so being, there's no wrong answer. It's just understanding your client's needs. Is there a better fit?   And I think that's, that's, that's my wish, that people don't see conversation as something that you do at the beginning to build a rapport, but that it's worthy of being an intervention target. It should be most people's primary goal. I think, right, when we ask, what is it you'd like? “I want to talk more. I want to have a conversation.” Audrey Holland would say it's a moral imperative to to treat the conversation and to listen to folks' stories. So just to think carefully about what it is your client wants to achieve, and if there's an environment in which that might be easier to help them achieve that.   Lyssa Rome It's interesting, as you were saying that I was thinking about what you said earlier on about sort of convincing funders about the value of group treatment, but what you're saying now makes me think that it's all your work is also valuable in convincing speech therapists that referrals to groups or dyads is valuable and and also for people with aphasia and their families that it's worth seeking out.   I'm curious about where in the continuum of care this started for the people who were in your trial. I mean, were these people with chronic aphasia who had had strokes years earlier? Was it a mix? And did that make a difference?   Liz Hoover It was a mix. I think our earliest participant was six months post-onset. Our most chronic participant was 26 years post-onset. So a wide range. We want, obviously, from a study perspective, we needed folks to be outside of the traditional window of spontaneous recovery in stroke-induced aphasia.   But it was important to us to have a treatment dose that was reasonable and applicable to a United States healthcare climate, right? So twice a week for an hour is something that people would get reimbursed for. The overall dose is the minimum that's been shown to be effective in the RELEASE collaborative trial papers. And then, you know, but still, half, less than half the dose that the Elman and Bernstein Ellis study found to be effective. So there may be some wiggle room there to see if, if a larger dose is more effective.   But yeah, I think it's that idea of finding funding, convincing people that this is not just a reasonable treatment approach, but a good approach for many outcomes for people with chronic aphasia. I mean, you know, one of the biggest criticisms we hear from the giants in our field is the frustration with aphasia being treated like it's a quick fix and can be done. But you know, so much of the work shows that people are only just beginning to understand their condition by the time they're discharged from traditional outpatient services. And so there's a need for ongoing treatment indefinitely, I think, as your goals change, as you age, and as your wish to participate in different things changes over a lifetime,   Lyssa Rome Yeah, absolutely. And I think too, when we think about sort of the role of hope, if you know, if there is additional evidence showing that there can be change after that sort of traditional initial period, when we think that change happens the most, that can provide a lot of hope and motivation, I think, to people.   Liz Hoover yeah, we're look going to be looking next at predictors of change, so looking at our study entrance scores and trying to identify which participants were the responders versus the non-responders that you know, because group effects are one thing, but it's good to see who seems to benefit the most from these individual types of environments.   And an early finding is that confidence, or what some people in the field, I'm learning now are referring to as actually communication self-efficacy, but that previous exposure to group potentially and that confidence in your communication is inversely correlated with benefits from treatment on other measures. So if you've got a low confidence in your ability to communicate functionally in different environments, you're predicted to be a responder to conversation treatment.   Lyssa Rome Oh, that's really interesting. What else are you looking forward to working on when it comes to this data set or other projects that you have going on?   Liz Hoover Yeah. So as I mentioned, there's a lot of data still for us to dig into, looking at those individual responders or which factors or variables might make an impact. There is the very next on the list, we're also going to be looking very shortly at the dialogic conversation outcomes. So, it's a conversation treatment. How has conversation changed? That's a question we need to answer. So we're looking at that currently, and might look more closely at other measures. And then I think the question of the dose is an interesting one. The question of how individual variables or the saliency of the group may impact change is another potentially interesting question. There are many different directions you can go.   You know, we've got 193 participants in the study, with three separate testing time points, so it's a lot of data to look at still. And I think we want to be sure we understand what we're looking at, and what those active ingredients might be, that we've got the constructs well defined before we start to recruit for another study and to expand on these findings further.   Lyssa Rome When we were meeting earlier, getting ready for this talk, you mentioned to me a really valuable video resource, and I wanted to make sure we take some time to highlight that. Can you tell us a little bit about what you worked on with your colleagues at Boston University?   Liz Hoover Yes, thank you. So I'll tell you a little bit. We have a video education series. Some of you may have heard about this already, but it's up on our website so bu.edu/aphasiacenter, and we'll still share that link as well. And it's a series of short, aphasia-friendly videos that are curated by our community to give advice and share lived experiences from people with aphasia and their care partners.   This project came about right on the heels of the COVID shutdown at our university. I am involved in our diagnostic clinic, and I was seeing folks who had been in acute care through COVID being treated with people who were wearing masks, who had incredibly shortened lengths of stay because people you know rightly, were trying to get them out of a potentially vulnerable environment. And what we were seeing is a newly diagnosed cohort of people with aphasia who were so under-informed about their condition, and Nina that has a famous quote right of the public being woefully uninformed of the aphasia condition and you don't think it can get any worse until It does.   And I thought, gosh, wouldn't it be wonderful to be able to point them to some short education videos that are by people who have lived their same journey or a version of their same journey. So we fundraised and collaborated with a local production company to come up with these videos. And I'll share, Lyssa, we just learned last week that this video series has been awarded the ASHA 2025 Media Outreach Award. So it's an award winning series.   Lyssa Rome Yeah, that's fantastic, and it's so well deserved. They're really beautifully and professionally produced. And I think I really appreciated hearing from so many different people with aphasia about their experiences as the condition is sort of explained more. So thank you for sharing those and we'll put the links in our show notes along with links to the other articles that you've mentioned in this conversation in our show notes. So thanks.   Liz Hoover Yeah, and I'll just put a big shout out to my colleague, Jerry Kaplan, who's the amazing interviewer and facilitator in many of these videos, and the production company, which is Midnight Brunch. But again, the cinematography and the lighting. They're beautifully done. I think I'm very, very happy with them.   Lyssa Rome Yeah, congrats again on the award too. So to wrap up, I'm wondering if there's anything else that you want listeners to take away from this conversation or from the work that you've been doing on conversation treatments.   Liz Hoover I would just say that I would encourage everybody to try group treatment. It's a wonderful option for intervention for people, and to remind everyone of Barbara Shadden and Katie Strong's work, of that embedded storytelling that can come out in conversation, and of the wonderful Audrey Holland's words, of it being a moral imperative to help people tell their story and to converse. It's yeah… You'll drink the Kool Aid if you try it. Let me just put it that way. It's a wonderful intervention that seems to be meaningful for most clients I've ever had the privilege to work with.   Lyssa Rome I agree with that. And meaningful too, I think for clinicians who get to do the work.   Liz Hoover, thank you so much for your work and for coming to talk with us again, for making your second appearance on the podcast. It's been great talking with you.   Liz Hoover Thank you. It's been fun. I appreciate it.   Lyssa Rome And thanks also to our listeners for the references and resources mentioned in today's show. Please see our show notes. They're available on our website, www.aphasiaaccess.org. There, you can also become a member of our organization, browse our growing library of materials and find out about the Aphasia Access Academy. If you have an idea for a future podcast episode, email us at info@aphasia access.org.   Thanks again for your ongoing support of Aphasia Access. For Aphasia Access Conversations. I'm Lyssa Rome.       Resources Walker-Batson, D., Curtis, S., Smith, P., & Ford, J. (1999). An alternative model for the treatment of aphasia: The Lifelink© approach. In R. Elman (Ed.), Group treatment for neurogenic communication disorders: The expert clinician's approach (pp. 67-75). Woburn, MA: Butterworth-Heinemann   Hoover, E.L., DeDe, G., Maas, E. (2021). A randomized controlled trial of the effects of group conversation treatment on monologic discourse in aphasia. Journal of Speech-Language and Hearing Research doi/10.1044/2021_JSLHR-21-00023 Hoover, E., Szabo, G., Kohen, F., Vitale, S., McCloskey, N., Maas, E., Kularni, V., & DeDe., G. (2025). The benefits of conversation group treatment for individuals with chronic aphasia: Updated evidence from a multisite randomized controlled trial on measures of language and communication. American Journal of Speech Language Pathology. DOI: 10.1044/2025_AJSLP-24-00279   Aphasia Resource Center at BU   Living with Aphasia video series Aphasia Access Podcast Episode #15: In Conversation with Liz Hoover

Plate tectonics tells us all about how the continents are drifting along at a centimeter or two a year, ever so gradually reshaping the surface of the earth, remaking the ocean floor, and causing earthquakes and volcanoes the world over. But what if it went a lot faster? In this episode, Todd and Paul chat with geophysicist Sarah Peterson about the CATASTROPHIC version of plate tectonics that has become the leading model of how the Flood happened. Sarah walks us through both the basic concepts of tectonics and how Catastrophic Plate Tectonics explains even more than the slow, conventional version. If you've ever wondered how volcanoes, earthquakes, and continental drift fit in the creation model, this episode is for you!Papers mentioned in this episodePetersen, Sarah and Baumgardner, John (2023) "Catastrophic Plate Tectonics and the Tectonics of Western North America," Proceedings of the International Conference on Creationism: Vol. 9, Article 33.DOI: 10.15385/jpicc.2023.9.1.54Available at: https://digitalcommons.cedarville.edu/icc_proceedings/vol9/iss1/33Austin, Steven A.; Baumgardner, John R.; Humphreys, D. Russell; Snelling, Andrew A.; Vardiman, Larry; and Wise, Kurt P. (1994) "Catastrophic Plate Tectonics: A Global Flood Model of Earth History," Proceedings of the International Conference on Creationism: Vol. 3, Article 56.Available at: https://digitalcommons.cedarville.edu/icc_proceedings/vol3/iss1/56Baumgardner, John R. (1994) "Computer Modeling of the Large Scale Tectonics Associated With the Genesis Flood," Proceedings of the International Conference on Creationism: Vol. 3, Article 15.Available at: https://digitalcommons.cedarville.edu/icc_proceedings/vol3/iss1/15Baumgardner, John R. (1994) "Runaway Subduction as the Driving Mechanism for the Genesis Flood," Proceedings of the International Conference on Creationism: Vol. 3, Article 14.Available at: https://digitalcommons.cedarville.edu/icc_proceedings/vol3/iss1/14

A rerun!! Doi!! Cause I've known Emilie for years now!!

In this episode of Communicable, Angela Huttner and Erin McCreary invite two titans of vaccinology, Barney Graham (Atlanta, USA), former deputy director of the NIH NIAID Vaccine Research Center and architect of the mRNA vaccines against COVID-19, and Gary Kobinger (Galveston, USA), leading virologist in the development of the first effective Ebola vaccine, rVSV-ZEBOV, for a candid conversation about their direct experience building two of the most well known vaccines to date, and deploying them to the public. The episode also reviews the different vaccine platforms and addresses vaccine hesitancy, equitable access to vaccines, and global health equity. This episode was edited by Kathryn Hostettler and peer reviewed by Eren Ozturk of Ankara University, Ankara, Türkiye.  Terms and sourcesVSV, vesicular stomatitis virusZEBOV, Zaire Ebolavirus rVSV-ZEBOV, recombinant vesicular stomatitis virus expressing the (Zaire) Ebolavirus glycoprotein (vaccine)VRC, the NIH Vaccine Research Center of NIAID Morehouse School of Medicine Satcher Global Health Equity InstituteGuardRX, https://www.guardrx.org/en/who-we-are/ ReferencesMarzi A, et al. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science 2015. DOI: 10.1126/science.aab3920 Agnandji S, Huttner A, Zinser M, et al. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. New Engl J Med 2015. DOI: 10.1056/NEJMoa1502924Graham BS and Corbett KS. Prototype pathogen approach for pandemic preparedness: world on fire. J Clin Invest 2020. DOI: 10.1172/JCI139601Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. New Engl J Med 2020. DOI: 10.1056/NEJMoa2022483

We have a wonderful podacst community! Within 24 hours of our immediate past episode release, one close friend- and fellow OBGYN, Dr. Eric Colton (OB Hospitalist Group) reached out and shared valuable words of wisdom regarding a potentially deadly complication of the CS-scar defect...the CS scar ectopic pregnancy. Listen in for Dr. Colton's cameo and details. 1. Ban, Yanli MD, PhD; Shen, Jia MD; Wang, Xia MD; Zhang, Teng MD, PhD; Lu, Xuxu MD; Qu, Wenjie MD; Hao, Yiping MD; Mao, Zhonghao MD; Li, Shizhen MD; Tao, Guowei MD, PhD; Wang, Fang MD, PhD; Zhao, Ying MD, PhD; Zhang, Xiaolei MD, PhD; Zhang, Yuan MD, PhD; Zhang, Guiyu MD, PhD; Cui, Baoxia MD, PhD. Cesarean Scar Ectopic Pregnancy Clinical Classification System With Recommended Surgical Strategy. Obstetrics & Gynecology 141(5):p 927-936, May 2023. | DOI: 10.1097/AOG.0000000000005113

We recap some of our recent travels, and then chat about bearded dragons. A new study shows that these lizards are making decisions about how they maintain their body temperature, and this has a knock-on effect on how well they perform during their daily lives. Being cold-blooded is complicated. Become a Patreon: https://www.patreon.com/herphighlights Merch: https://www.redbubble.com/people/herphighlights/shop Full reference list available here: http://www.herphighlights.podbean.com Main Paper References: Wild KH, Roe JH, Curran J, Pearson PR, Schwanz L, Georges A, Sarre SD. 2025. Thermal performance curves, activity and survival in a free‐ranging ectotherm. Journal of Animal Ecology. DOI: 10.1111/1365-2656.70091. Species of the Bi-Week: Petzold A, Glaw F, Mullin KE, Rakotoarison A, Raselimanana AP, Cottini A, Orozco-terWengel P, Kohler J, Protzel D, Vences M, Hofreiter M, Scherz MD. 2025. A preliminary assessment of the diversity in the frog genus Anilany (Microhylidae: Cophylinae) with description of a new species from western Madagascar. Salamandra. Other Mentioned Papers/Studies: Marshall BM, Strine CT, Gore ML, Eskew EA, Stringham OC, Cardoso P, Chekunov S, Watters F, Fukushima C, García-Díaz P, Sinclair JS, Tlusty MF, Almeida RJ, Valdez JW, Hughes AC. 2025. Mapping the global dimensions of US wildlife imports. Current Biology:S0960982225008784. DOI: 10.1016/j.cub.2025.07.012. Editing and Music: Intro/outro – Treehouse by Ed Nelson Species Bi-week theme – Michael Timothy Other Music – The Passion HiFi, https://www.thepassionhifi.com

Episode SummaryErin and Rachel wallow through an elderly man's grief journey with Pixar's critically acclaimed Up (2009). They argue the beautiful art and cute sidekicks aren't enough to redeem this (admittedly beloved) film, especially since the (admittedly moving) love story invokes the classic “dead wife” trope. We'll keep sailing our balloon house onto the next one, please and thank you. Episode BibliographyAdler, S. (2008, August 7). 'Up' And Coming: 3-D Pixar Movie Tells A 'Coming Of Old Age' Story, Director Says. MTV. https://web.archive.org/web/20100318060539/http://www.mtv.com/movies/news/articles/1592302/story.jhtmlThe Associated Press. (2009, May 12). Q&A: Pete Docter. The Hollywood Reporter. https://www.hollywoodreporter.com/business/business-news/qampa-pete-docter-83783/Berardinelli, J. (2009, May 26). Up (United States, 2009). ReelViews. https://www.reelviews.net/reelviews/upBlock, A. B. (2009, November 17). Anatomy of a Contender: ‘Up'. The Hollywood Reporter. https://www.hollywoodreporter.com/business/business-news/anatomy-contender-91440/Brooks, X. (2009, March 19). Curtain will go Up on this year's Cannes with 3-D yarn | Cannes 2009. The Guardian. https://www.theguardian.com/film/2009/mar/19/up-first-animation-to-open-cannes-film-festivalChen, D. (2009, May 28). Marketing Up's Asian-American Lead Character. SlashFilm. https://www.slashfilm.com/503927/marketing-ups-asian-american-lead-character/Coconut Press. (2023, August 16). The Making of Up: Pixar Travels to Venezuela 4k. YouTube. https://www.youtube.com/watch?v=jXCHlcrMgLYCorliss, R. (2009, May 7). Going Up. TIME. https://web.archive.org/web/20090513203932/http://www.time.com/time/arts/article/0,8599,1896685-1,00.htmlCorliss, R. (2009, May 28). Up, Up and Away: Another New High for Pixar. Time Magazine. https://time.com/archive/6688401/up-up-and-away-another-new-high-for-pixar/Docter, P. (Director). (2009). Up [Film]. Pixar Animation Studios.DVDFilmBonus. (2023, July 16). Up 2009 ( Pixar ) Making of & Behind the Scenes. YouTube. https://www.youtube.com/watch?v=hPQuzPm73foErikson E.H., & Erikson, J.M. (1982). Life cycle completed. W.W. Norton & CompanyFreer, I. (2009, October 3). Up. Empire Online. https://www.empireonline.com/movies/reviews/movie-2-review/Hartlaub, P. (2009, May 27). Oakland's Fentons Creamery in Pixar film 'Up'. SFGate. https://www.sfgate.com/entertainment/article/Oakland-s-Fentons-Creamery-in-Pixar-film-Up-3297072.phpHauser, T. (2016). The Art of Up. Chronicle Books LLC.Hogan, R. (2009, June 1). Pixar's Up review. Den of Geek. https://www.denofgeek.com/movies/pixars-up-review-2/Horn, J. (2009, May 10). up, up and away. Los Angeles Times. https://www.latimes.com/archives/la-xpm-2009-may-10-ca-up10-story.htmlHornaday, A. (2009, May 29). Up. The Washington Post. https://web.archive.org/web/20091027073954/http://www.washingtonpost.com/gog/movies/up,1156226.htmlKhoo, I. (2015, July 13). Pregnancy Loss: The Surprising Movie That Understands Miscarriage. HuffPost Canada. https://www.huffpost.com/archive/ca/entry/pregnancy-loss-the-surprising-movie-that-understands-miscarriag_n_7786224King, S. (2009, May 28). Jordan Nagai, 'Up'. Los Angeles Times. https://web.archive.org/web/20121106123435/http://articles.latimes.com/2009/may/28/entertainment/et-jordanpete28The Korean Face of Pixar's Latest Star. (2009, June 3). The Chosun Daily. https://www.chosun.com/english/people-en/2009/06/03/NXQOOEMZNUTRQNAZ7NTDTTGBUU/Ksieh, K. (2009, May 29). Jordan Nagai as Russell in UP. Channel APA. https://web.archive.org/web/20121110102130/http://www.channelapa.com/2009/05/jordan-nagai-as-russell-in-up.htmlMedia Action Network for Asian Americans. (2009, September 2). ASIAN AMERICAN MEDIA WATCHDOG GROUP PRAISES DISNEY/PIXAR'S "UP" FOR CREATING ASIAN AMERICAN PROTAGONIST. MANAA. https://web.archive.org/web/20090902105114/http://www.manaa.org/up_press_release.htmlMeinel, D. (2014). Empire is out there!?: The spirit of imperialism in the Pixar animated film ‘Up'. Traces. NECSUS. https://necsus-ejms.org/empire-spirit-imperialism-pixar-animated-film/#_edn12Meinel, D. (2016). Pixar's America. Palgrave MacMillan. DOI: 10.1007/978-3-319-31634-5_7Morgenstern, J. (2009, May 14). Reaching for the Sky, 'Up' Fails to Soar - WSJ. The Wall Street Journal. https://www.wsj.com/articles/SB124226358415817813Piane, C. (2010, April 9). EWP Honors Pixar Films And Jordan Nagai At 44th Anniversary Visionary Awards 4/19. Broadway World. https://www.broadwayworld.com/los-angeles/article/EWP-Honors-Pixar-Films-And-Jordan-Nagai-At-44th-Anniversary-Visionary-Awards-419-20100409Press Release. (2009, November 8). Interview: Pete Doctor on Disney/Pixar's UP. Major Spoilers. https://web.archive.org/web/20100208140509/http://www.majorspoilers.com/archives/27376.htm/Rechtshaffen, M. (2009, May 12). Up - Film Review. The Hollywood Reporter. https://web.archive.org/web/20120315171219/http://www1.hollywoodreporter.com/hr/film-reviews/up-film-review-1003972156.storySchilling, V. (2019, September 15). Boy Scouts ‘have been one of the worst culprits' of cultural appropriation. ICT. https://ictnews.org/news/boy-scouts-have-been-one-of-the-worst-culprits-of-cultural-appropriation/Tell Me More Staff. (2013, September 9). Angry Asian Man Not So Angry : Code Switch. NPR. https://www.npr.org/sections/codeswitch/2013/09/09/219725276/angry-asian-man-not-so-angryUp (2009 film). (n.d.). Wikipedia. https://en.wikipedia.org/wiki/Up_(2009_film)Wooden, S.R., & Gillam, K. (2014). Pixar's boy stories: Masculinity in a postmodern age. Rowman & Littlefield Publishers. Young, S. (2020, January 16). Exploring the dead wives in family movies trope. Nerdist. https://nerdist.com/article/dead-wives-family-movies-dolittle/Zacharek, S. (2009, May 29). Up. Salon. https://www.salon.com/2009/05/29/up_review/

Contributor: Alec Coston, MD Educational Pearls: Hepatic encephalopathy (HE) is defined as a disruption in brain function that results from impaired liver function or portosystemic shunting. Manifests as various neurologic and psychiatric symptoms such as confusion, inattention, and cognitive dysfunction Although ammonia levels have historically been recognized as important criteria for HE, the diagnosis is ultimately made clinically. An elevated ammonia level lacks sensitivity and specificity for HE Trends in ammonia levels do not correlate with disease improvement or resolution A 2020 study published in the American Journal of Gastroenterology evaluated 551 patients diagnosed with hepatic encephalopathy and treated with standard therapy Only 60% of patients had an elevated ammonia level, demonstrating the limitations of ammonia levels However, a normal ammonia level in a patient with concern for HE should raise suspicion for other pathology. In patients with cirrhosis presenting with neuropsychiatric symptoms, consider HE as the diagnosis after excluding other potential causes of altered mental status (i.e., Seizure, infection, intracranial hemorrhage) The primary treatment is lactulose Works by acidifying the gastrointestinal tract. Ammonia (NH₃) is converted into ammonium (NH₄⁺), which is poorly absorbed and subsequently eliminated from the body Also exerts a laxative effect, further enhancing elimination References: Haj M, Rockey DC. Ammonia Levels Do Not Guide Clinical Management of Patients With Hepatic Encephalopathy Caused by Cirrhosis. Am J Gastroenterol. 2020 May;115(5):723-728. doi: 10.14309/ajg.0000000000000343. PMID: 31658104. Lee F, Frederick RT. Hepatic Encephalopathy-A Guide to Laboratory Testing. Clin Liver Dis. 2024 May;28(2):225-236. doi: 10.1016/j.cld.2024.01.003. Epub 2024 Jan 30. PMID: 38548435. Vilstrup, Hendrik1; Amodio, Piero2; Bajaj, Jasmohan3,4; Cordoba, Juan1,5; Ferenci, Peter6; Mullen, Kevin D.7; Weissenborn, Karin8; Wong, Philip9. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver. Hepatology 60(2):p 715-735, August 2014. | DOI: 10.1002/hep.27210 Weissenborn K. Hepatic Encephalopathy: Definition, Clinical Grading and Diagnostic Principles. Drugs. 2019 Feb;79(Suppl 1):5-9. doi: 10.1007/s40265-018-1018-z. PMID: 30706420; PMCID: PMC6416238. Summarized by Ashley Lyons, OMS3 | Edited by Ashley Lyons & Jorge Chalit, OMS4 Get your tickets to Tox Talks Event, Sept 11, 2025: https://emergencymedicalminute.org/events-2/ Donate: https://emergencymedicalminute.org/donate/  

Welcome back to Open The Voice Gate! Case (https://twitter.com/_inyourcase) and Mike (https://twitter.com/fujiiheya) are back with an update on the comings and goings of Dragongate.It's 25 Years of Naruki Doi as Dragongate returns to Nara (8/30) for his homecoming show and OTVG spend the episode celebrating the Runaway Muscle. Case and Mike ask some big questions about his career, discuss what makes Doi unique, and review two extra Doi matches, his Dream Gate defense against Koji Kanemoto in 2009 and his second Dream Gate title win against Ben-K!Match links can be found at voicesofwrestling.com or in the Open The Voice Gate channel in VOW's Discord!Our podcast provider, Red Circle, offers the listeners the option to sponsor the show. Click on “Sponsor This Podcaster” at https://redcircle.com/shows/open-the-voice-gate and you can donate a single time, or set up a monthly donation to Open The Voice Gate!Please Rate and Review Open The Voice Gate on the podcast platform of your choice and follow us on twitter at https://twitter.com/openvoicegate.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Today we're joined by leading Psilocybin and Psychedelic Law attorney Robert Rush of Rights and Reason Project. We discuss DOI and DOC, the potential rescheduling of Psilocybin from Schedule 1 to Schedule 2 under the Controlled Substances Act, psychedelic churches, the limits of decriminalization, the potential prohibition of 7-OH, and more. Please rate and review this episode wherever you're listening ( : Hosted on Acast. See acast.com/privacy for more information.

Mahmoud Alwakeel, MD, joins CHEST® Journal Podcast Moderator Alice Gallo De Moraes, MD, FCCP, to discuss his research into the impact of the COVID-19 pandemic on the performance of pulmonary and critical care medicine fellows on the in-training examination.  DOI: 10.1016/j.chest.2025.04.015 Disclaimer: The purpose of this activity is to expand the reach of CHEST content through awareness, critique, and discussion. All articles have undergone peer review for methodologic rigor and audience relevance. Any views asserted are those of the speakers and are not endorsed by CHEST. Listeners should be aware that speakers' opinions may vary and are advised to read the full corresponding journal article(s) for complete context. This content should not be used as a basis for medical advice or treatment, nor should it substitute the judgment used by clinicians in the practice of evidence-based medicine. 

In the last 2 episodes we covered new updates in menopausal hormone therapy. However, we did not address TESTOSTERONE use. This episode idea comes from one our podcast family members and good friend, Eric. Eric is 100% correct: Testosterone replacement, when done correctly, has come along way. When is this indicated? Is this endorsed by professional medical/endocrine groups? What's the dose? We have fun stuff to review, so listen in!1. Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019 Oct 1;104(10):4660-4666. doi: 10.1210/jc.2019-01603. PMID: 31498871; PMCID: PMC6821450.2. Sharon J. Parish, James A. Simon, Susan R. Davis, Annamaria Giraldi, Irwin Goldstein, Sue W. Goldstein, Noel N. Kim, Sheryl A. Kingsberg, Abraham Morgentaler, Rossella E. Nappi, Kwangsung Park, Cynthia A. Stuenkel, Abdulmaged M. Traish, Linda Vignozzi, International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women, The Journal of Sexual Medicine, Volume 18, Issue 5, May 2021, Pages 849–867, https://doi.org/10.1016/j.jsxm.2020.10.0093. Levy, Barbara MD, MSCP; Simon, James A. MD, MSCP. A Contemporary View of Menopausal Hormone Therapy. Obstetrics & Gynecology 144(1):p 12-23, July 2024. | DOI: 10.1097/AOG.00000000000055534. NAMS The 2022 hormone therapy position statement of The North American Menopause Society: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://menopause.org/wp-content/uploads/professional/nams-2022-hormone-therapy-position-statement.pdf

Estevanico was a translator and guide, and was probably the first person of any race from outside the Americas to enter what’s now Arizona and New Mexico – which happened in 1539. Research: Birzer, Dedra McDonald and J.M.H. Clark. “Esteban Dorantes.” Peoples of the Historical Slave Trade. Journal of Slavery and Data Preservation. https://enslaved.org/fullStory/16-23-92882/ Birzer, Dedra McDonald. "Esteban." Oxford African American Studies Center. May 31, 2013. Oxford University Press. Date of access 30 Jul. 2025, https://oxfordaasc.com/view/10.1093/acref/9780195301731.001.0001/acref-9780195301731-e-34375 Chipman, Donald E. and Robert S. Wedd. “How Historical Myths Are Born...... And Why They Seldom Die.” The Southwestern Historical Quarterly , January, 2013. https://www.jstor.org/stable/24388345 Clark, J.M.H. "Esteban the African ‘Estebanico’." Oxford African American Studies Center. May 31, 2017. Oxford University Press. Date of access 30 Jul. 2025, https://oxfordaasc.com/view/10.1093/acref/9780195301731.001.0001/acref-9780195301731-e-73900 Docter, Mary. “Enriched by Otherness: The Transformational Journey of Cabeza de Vaca.” Christianity and Literature , Autumn 2008, Vol. 58, No. 1. Via JSTOR. https://www.jstor.org/stable/44313875 "Estevanico (1500-1539)." Encyclopedia of World Biography, Gale, 1998. Gale Academic OneFile, link.gale.com/apps/doc/A148426031/GPS?u=mlin_n_melpub&sid=bookmark-GPS&xid=41f83344. Accessed 28 July 2025. Flint, Richard. “Dorantes, Esteban de.” New Mexico Office of the State Historian. Via archive.org. https://web.archive.org/web/20110728080635/http://www.newmexicohistory.org/filedetails.php?fileID=464 Gordon, Richard A. “Following Estevanico: The Influential Presence of an African Slave in Sixteenth-century New World Historiography.” Colonial Latin American Review Vol. 15, No. 2, December 2006. Gordon-Reed, Annette. “Estebanico’ s America.” The Atlantic. June 2021. Herrick, Dennis. “Esteban.” University of New Mexico Press. 2018. Project MUSE. https://muse.jhu.edu/book/60233. Ilahiane, Hsain. “Estevan de Dorantes, Estevanico: The First Moroccan and African Explorer of the American Southwest.” Southwest Center. Via YouTube. 2/21/2024. https://www.youtube.com/watch?v=RLm0BsFDfvk Ilahiane, Hsain. “Estevan De Dorantes, the Moor or the Slave? The other Moroccan explorer of New Spain.” The Journal of North African Studies, 5:3, 1-14, DOI: 10.1080/13629380008718401 Ladd, Edmund J. “Zuni on the Day the Men in Metal Arrived.” From The Coronado Expedition to Tierra Nueva. Shirley Cushing Flint and Richard Flint, eds. University Press of Colorado. 2004. https://muse.jhu.edu/book/3827 Logan, Rayford. “Estevanico, Negro Discoverer of the Southwest: A Critical Reexamination.” Phylon (1940-1956), Vol. 1, No. 4 (4th Qtr., 1940). Via JSTOR. https://www.jstor.org/stable/272298 Sando, Joe S. “Pueblo nations: eight centuries of Pueblo Indian history.” Santa Fe, N.M. : Clear Light. 1992. Shields, E. Thomson. "Esteban." Oxford African American Studies Center. December 01, 2006. Oxford University Press. Date of access 30 Jul. 2025, https://oxfordaasc-com.proxy.bostonathenaeum.org/view/10.1093/acref/9780195301731.001.0001/acref-9780195301731-e-17021 Simour, Lhoussain. “(De)slaving history: Mostafa al-Azemmouri, the sixteenth-century Moroccan captive in the tale of conquest.” European Review of History—Revue europe´enne d’histoire, 2013 Vol. 20, No. 3. http://dx.doi.org/10.1080/13507486.2012.745830 Smith, Cassander L. “Beyond the Mediation: Esteban, Cabeza de Vaca's ‘Relación’ , and a Narrative Negotiation.” Early American Literature , 2012, Vol. 47, No. 2. Via JSTOR. https://www.jstor.org/stable/41705661 See omnystudio.com/listener for privacy information.